
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/207322/

Deposited on: 8 January 2020
Genome wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders.

Cross-Disorder Group of the Psychiatric Genomics Consortium*

* Author lists are provided at the end of the manuscript

Correspondence to:
Phil H. Lee, PhD
Psychiatric and Neurodevelopmental Genetics Unit
Center for Genomic Medicine, Massachusetts General Hospital
185 Cambridge St.
Boston, MA 02114
plee0@mgh.harvard.edu

Jordan W. Smoller, MD, ScD
Psychiatric and Neurodevelopmental Genetics Unit
Center for Genomic Medicine, Massachusetts General Hospital
185 Cambridge St.
Boston, MA 02114
jsmoller@mgh.harvard.edu
Summary

Genetic influences on psychiatric disorders transcend diagnostic boundaries, suggesting substantial pleiotropy of contributing loci. However, the nature and mechanisms of these pleiotropic effects remain unclear. We performed a meta-analysis of 232,964 cases and 494,162 controls from genome-wide studies of anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome. Genetic correlation analyses revealed a meaningful structure within the eight disorders identifying three groups of inter-related disorders. We detected 109 loci associated with at least two psychiatric disorders, including 23 loci with pleiotropic effects on four or more disorders and 11 loci with antagonistic effects on multiple disorders. The pleiotropic loci are located within genes that show heightened expression in the brain throughout the lifespan, beginning in the second trimester prenatally, and play prominent roles in a suite of neurodevelopmental processes. These findings have important implications for psychiatric nosology, drug development, and risk prediction.

Keywords

Psychiatric genetics, cross-disorder genetics, psychiatric disorders, pleiotropy, neurodevelopment, GWAS, genetic correlation, gene expression
INTRODUCTION

Psychiatric disorders affect more than 25% of the population in any given year and are a leading cause of worldwide disability (Global Burden of Disease Injury Incidence Prevalence Collaborators, 2017; Kessler and Wang, 2008). The substantial influence of genetic variation on risk for a broad range of psychiatric disorders has been established by both twin and, more recently, large-scale genomic studies (Smoller et al., 2018). Psychiatric disorders are highly polygenic, with a large proportion of heritability contributed by common variation. Many risk loci have emerged from genome-wide association studies (GWAS) of, among others, schizophrenia (SCZ), bipolar disorder (BIP), major depression (MD), and attention-deficit/hyperactivity disorder (ADHD) from the Psychiatric Genomics Consortium (PGC) and other efforts (Sullivan et al., 2018). These studies have revealed a surprising degree of genetic overlap among psychiatric disorders (Brainstorm Consortium, 2018; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). Elucidating the extent and biological significance of cross-disorder genetic influences has implications for psychiatric nosology, drug development, and risk prediction. In addition, characterizing the functional genomics of cross-phenotype genetic effects may reveal fundamental properties of pleiotropic loci that differentiate them from disorder-specific loci, and help identify targets for diagnostics and therapeutics.

In 2013, analyses by the PGC’s Cross-Disorder Group identified loci with pleiotropic effects across five disorders: autism spectrum disorder (ASD), ADHD, SCZ, BIP, and MD in a sample comprising 33,332 cases and 27,888 controls (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). In the current study, we examined pleiotropic effects in a greatly expanded dataset, encompassing 232,964 cases and 494,162 controls, that included three additional psychiatric disorders: Tourette syndrome (TS), obsessive-compulsive disorder (OCD), and anorexia nervosa (AN). We address four major questions regarding the shared genetic basis of these eight disorders: 1) Can we identify a shared etiologic structure within the broad range of these clinically distinct psychiatric disorders? 2) Can we detect additional loci associated with risk for multiple disorders (pleiotropic loci)? 3) Do some of these risk loci have opposite allelic effects across disorders? and 4) Can we identify functional features of the pleiotropic loci that could account for their broad effects on psychopathology?

RESULTS

We analyzed genome-wide single nucleotide polymorphism (SNP) data for eight neuropsychiatric disorders using a combined sample of 232,964 cases and 494,162 controls (Table 1; Supplementary Table 1). The eight disorders included AN (Duncan et al., 2017), ASD (Grove et al., 2017), ADHD (Demontis et al., 2019), BIP (Stahl et al.,
2018), MD (Wray et al., 2018), OCD (International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS), 2018), TS (Yu et al., In press.), and SCZ (Schizophrenia Working Group of the Psychiatric Genomics, 2014). All study participants were of self-identified European ancestry, which was supported by principal component analysis of genome-wide data.

**Table 1. Summary of eight neuropsychiatric disorder datasets**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>#Cases</th>
<th>#Controls</th>
<th>Total Samples</th>
<th># of GWAS Loci</th>
<th>Population Prevalence (k)</th>
<th>Liability-based SNP heritability (SE)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>19,099</td>
<td>34,194</td>
<td>53,293</td>
<td>9</td>
<td>0.05</td>
<td>0.222 (0.014)</td>
<td>Demontis et al. 2019</td>
</tr>
<tr>
<td>AN</td>
<td>3,495</td>
<td>10,983</td>
<td>14,478</td>
<td>0</td>
<td>0.01</td>
<td>0.195 (0.029)</td>
<td>Duncan et al. 2017</td>
</tr>
<tr>
<td>ASD</td>
<td>18,381</td>
<td>27,969</td>
<td>46,350</td>
<td>5</td>
<td>0.01</td>
<td>0.113 (0.010)</td>
<td>Grove et al. 2017</td>
</tr>
<tr>
<td>BIP</td>
<td>20,352</td>
<td>31,358</td>
<td>51,710</td>
<td>17</td>
<td>0.01</td>
<td>0.182 (0.011)</td>
<td>Stahl et al. 2018</td>
</tr>
<tr>
<td>MD</td>
<td>130,664</td>
<td>330,470</td>
<td>461,134</td>
<td>44</td>
<td>0.15</td>
<td>0.085 (0.004)</td>
<td>Wray et al. 2018</td>
</tr>
<tr>
<td>OCD</td>
<td>2,688</td>
<td>7,037</td>
<td>9,725</td>
<td>0</td>
<td>0.025</td>
<td>0.280 (0.041)</td>
<td>IOCDF-GC and OCGAS 2018</td>
</tr>
<tr>
<td>SCZ</td>
<td>33,640</td>
<td>43,456</td>
<td>77,096</td>
<td>108</td>
<td>0.01</td>
<td>0.222 (0.012)</td>
<td>Schizophrenia Working Group of PGC. 2014</td>
</tr>
<tr>
<td>TS</td>
<td>4,645</td>
<td>8,695</td>
<td>13,340</td>
<td>0</td>
<td>0.008</td>
<td>0.200 (0.026)</td>
<td>Yu et al. 2018</td>
</tr>
<tr>
<td>Total</td>
<td>232,964</td>
<td>494,162</td>
<td>727,126</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The number of cases and controls used in the meta-analysis of the present study. The numbers may differ from those reported in the original publications because our study included only European ancestry subjects to avoid potential confounding due to ancestral heterogeneity across distinct disorder studies. SNP heritability was estimated from the GWAS summary statistics using LD score regression.

**Genetic correlations among eight neuropsychiatric disorders indicate three genetic factors.**

After standardized and uniform quality control, additive logistic regression analyses were performed on individual disorders (Methods). A total of 6,786,994 SNPs were common across all datasets and were retained for further study. Using the summary statistics of these SNPs, we first estimated pairwise genetic correlations among the eight disorders using linkage disequilibrium (LD) score regression analyses (Bulik-
The results were broadly concordant with previous estimates (Brainstorm Consortium, 2018; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). The genetic correlation was highest between SCZ and BIP ($r_g = 0.70 \pm 0.02$), followed by OCD and AN ($r_g = 0.50 \pm 0.12$). Interestingly, based on genome-wide genetic correlations, MD was closely correlated with ASD ($r_g = 0.45 \pm 0.04$) and ADHD ($r_g = 0.44 \pm 0.03$), two childhood-onset disorders. Despite variation in magnitude, significant genetic correlations were apparent for most pairs of disorders, suggesting a complex, higher-order genetic structure underlying psychopathology (Fig. 1b).

We modeled the genome-wide joint architecture of the eight neuropsychiatric disorders using an exploratory factor analysis (EFA) (Gorsuch, 1988), followed by genomic structural equation modeling (SEM) (Grotzinger et al., 2018) (Methods). EFA identified three correlated factors, which together explained 51% of the genetic variation in the eight neuropsychiatric disorders (Supplementary Table 3). The first factor consisted primarily of disorders characterized by compulsive behaviors, specifically AN, OCD, and, more weakly, TS. The second factor was characterized by mood and psychotic disorders (MD, BIP, and SCZ), and the third factor by three early-onset neurodevelopmental disorders (ASD, ADHD, TS) as well as MD. Similar to our EFA results, hierarchical clustering analyses also identified three sub-groups among the eight disorders (Supplementary Fig. 1).
Figure 1. Genetic relationships between eight psychiatric disorders. A) SNP-based genetic correlations ($r_g$) were estimated between eight neuropsychiatric disorders using LDSC. The size of the circles scales with the significance of the p-values. The darker the color, the larger the magnitude of $r_g$. 
Star sign (*) indicates statistical significance after Bonferroni correction. (B) SNP-based genetic correlations between eight disorders were depicted using an in-directed graph to reveal complex genetic relationships. Only significant genetic correlations after Bonferroni correction in (A) were displayed. Each node represents a disorder, with edges indicating the strength of the pairwise correlations. The width of the edges increases, while the length decreases, with the absolute values of $r_g$. (C) Based on results of an exploratory factor analysis of the genetic correlation matrix, a confirmatory factor model with three correlated genetic factors was specified using Genomic SEM and estimated with the weighted least squares algorithm. Two-headed arrows connecting the three factors to one another represent their correlations. Two-headed arrows connecting the genetic components of the individual psychiatric disorders to themselves represent residual genetic variances and correspond to the proportion of heritable variation liability to each individual psychiatric disorder that is unexplained by the three factors. Standardized parameters are depicted with their standard errors in parentheses. Paths labeled 1 with no standard errors reported are fixed parameters, which are used for scaling.

Cross-disorder meta-analysis identifies 109 pleiotropic loci

The factor structure described above is based on average effects across the genome, but does not address more fine-grained cross-disorder effects at the level of genomic regions or individual loci. To identify genetic loci with shared risk, we performed a meta-analysis of the eight neuropsychiatric disorders using a fixed-effects-based method (Bhattacharjee et al., 2012) that accounts for the differences in sample sizes, existence of subset-specific effects, and overlapping subjects across datasets (Methods). There was no evidence of genomic inflation ($\lambda_{1000} = 1.005$; Fig. 2a). Using the primary fixed-effects-based meta-analysis, we identified 136 LD-independent regions with genome-wide significant association ($P_{\text{meta}} \leq 5 \times 10^{-8}$). Due to the known extensive LD at the major histocompatibility complex (MHC) region (chromosome 6 region at 25-35 Mb), we considered the multiple signals present there as one locus. 101 of the 136 (74.3%) significantly associated regions overlapped with previously reported genome-wide significant regions from at least one individual disorder, while 35 loci (25.7%) represented novel genome-wide significant associations.
Figure 2. Results of cross-disorder meta-analysis and candidate gene mapping. (A) Quantile-quantile (QQ) plot displaying the observed meta-analysis statistics vs. the expected statistics under the null model of no associations in the -log_{10}(p-value) scale. Although a marked departure is notable between the two statistics, the estimated lambda_{1000} and the estimated LD Score regression intercept indicate that the observed inflation is mainly due to polygenic signals rather than major confounding factors including population stratification. (B) Gene prioritization strategies for significantly associated loci. Candidate genes were mapped on each locus if the index SNP and credible SNPs reside within a protein-coding gene, are eQTL markers of the gene in the brain tissue, or interact with promoter regions of the gene based on brain Hi-C data. (C) Manhattan plot displaying the cross-disorder meta-analysis results highlighting candidate genes mapped to top pleiotropic regions.

Within these 136 loci, multi-SNP-based conditional analysis (Yang et al., 2012) identified 10 additional SNPs with independent associations, resulting in a total of 146 independent lead SNPs (Supplementary Table 4). To provide a quantitative estimate of the best fit configuration of cross-disorder genotype-phenotype relationships, we estimated the posterior probability of association (referred to as the m-value) with each disorder using a Bayesian statistical framework (Han and Eskin, 2012) (Methods; Supplementary Table 5). As recommended, an m-value threshold of 0.9 was used to predict with high confidence that a particular SNP was associated with a given disorder. Also, m-values of < 0.1 were taken as strong evidence against association. Plots of the
SNP \( p \)-value vs. \( m \)-value for all 146 lead SNPs are shown in Supplementary Fig. 2. Nearly 75% (\( N = 109/146 \)) of the genome-wide significant SNPs were pleiotropic (i.e., associated with more than one disorder). As expected, configurations of disease association reflected the differences in the statistical power and genetic correlations between the samples (Supplementary Fig. 3). Of the 109 pleiotropic loci, 83% and 72% involved SCZ and BIP, respectively. MD, which had the largest case-control sample, was associated with 48% of the pleiotropic loci (\( N=52/109 \)). Despite the relatively small sample size, ASD was implicated in 36% of the pleiotropic loci. Most of the ASD associations co-occurred with SCZ and BIP. The other disorders, ADHD, TS, OCD, and AN featured associations in 16%, 14%, 11%, and 7% of the pleiotropic loci, respectively. Of the single-disorder-specific loci, 81% and 16% were associated with SCZ and MD, respectively.

Table 2 summarizes 23 pleiotropic loci associated with at least four of the disorders. Among these loci, heterogeneity of effect sizes was minimal (\( p \)-value of \( Q > 0.1 \)). Eleven of the 23 regions map to the intron of a protein-coding gene, and seven additional lead SNPs had at least one protein-coding gene within 100 kb. We used an array of functional genomics resources, including brain eQTL and Hi-C data (Wang et al., 2018; Won et al., 2016) to prioritize potential candidate genes to the identified regions (Methods; Fig. 2b). The Manhattan plot in Fig. 2c highlights the prioritized candidate genes.

<table>
<thead>
<tr>
<th>SNP</th>
<th>CHR</th>
<th>BP</th>
<th>Candidate Gene (evidence)</th>
<th>ADHD</th>
<th>ANO</th>
<th>ASD</th>
<th>BIP</th>
<th>MD</th>
<th>OCD</th>
<th>SCZ</th>
<th>TS</th>
<th>m</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs8084351</td>
<td>18</td>
<td>50726559</td>
<td>DCC(g,q)</td>
<td>0.961</td>
<td>0.905</td>
<td>0.97</td>
<td>0.965</td>
<td>1</td>
<td>0.951</td>
<td>1</td>
<td>0.984</td>
<td>8</td>
</tr>
<tr>
<td>rs7193263</td>
<td>16</td>
<td>6315880</td>
<td>RBFOX1(g)</td>
<td>0.924</td>
<td>0.802</td>
<td>0.984</td>
<td>0.995</td>
<td>1</td>
<td>0.902</td>
<td>0.901</td>
<td>0.932</td>
<td>7</td>
</tr>
<tr>
<td>rs12658451</td>
<td>5</td>
<td>10390437</td>
<td>-</td>
<td>0.963</td>
<td>0.165</td>
<td>0.999</td>
<td>0.972</td>
<td>1</td>
<td>0.574</td>
<td>1</td>
<td>0.963</td>
<td>6</td>
</tr>
<tr>
<td>rs34215985</td>
<td>4</td>
<td>42047778</td>
<td>SLC30A9(g; q)</td>
<td>0.908</td>
<td>0.926</td>
<td>0.992</td>
<td>0.843</td>
<td>1</td>
<td>0.88</td>
<td>0.929</td>
<td>0.913</td>
<td>6</td>
</tr>
<tr>
<td>rs61867293</td>
<td>10</td>
<td>106563924</td>
<td>SORCS3(g)</td>
<td>0.987</td>
<td>0.954</td>
<td>0.992</td>
<td>0.985</td>
<td>1</td>
<td>0.854</td>
<td>1</td>
<td>0.886</td>
<td>6</td>
</tr>
<tr>
<td>rs9360557</td>
<td>6</td>
<td>73132745</td>
<td>KCNQ5(5ha; hf)</td>
<td>0.905</td>
<td>0.938</td>
<td>0.976</td>
<td>0.984</td>
<td>0.993</td>
<td>0.897</td>
<td>1</td>
<td>0.892</td>
<td>6</td>
</tr>
<tr>
<td>rs10149470</td>
<td>14</td>
<td>104017953</td>
<td>-</td>
<td>0.844</td>
<td>0.833</td>
<td>0.998</td>
<td>0.979</td>
<td>1</td>
<td>0.868</td>
<td>0.997</td>
<td>0.97</td>
<td>5</td>
</tr>
<tr>
<td>rs11570190</td>
<td>11</td>
<td>57560452</td>
<td>CTNND1(g)</td>
<td>0.927</td>
<td>0.79</td>
<td>0.97</td>
<td>0.58</td>
<td>1</td>
<td>0.916</td>
<td>1</td>
<td>0.832</td>
<td>5</td>
</tr>
<tr>
<td>rs117956829</td>
<td>11</td>
<td>89339666</td>
<td>TRIM64B(ha)</td>
<td>0.723</td>
<td>0.929</td>
<td>0.972</td>
<td>0.906</td>
<td>1</td>
<td>0.66</td>
<td>0.997</td>
<td>0.789</td>
<td>5</td>
</tr>
<tr>
<td>rs1484144</td>
<td>4</td>
<td>80217597</td>
<td>-</td>
<td>0.97</td>
<td>0.884</td>
<td>0.973</td>
<td>0.98</td>
<td>1</td>
<td>0.84</td>
<td>0.998</td>
<td>0.85</td>
<td>5</td>
</tr>
<tr>
<td>rs6969410</td>
<td>7</td>
<td>110069015</td>
<td>-</td>
<td>0.836</td>
<td>0.827</td>
<td>0.987</td>
<td>0.93</td>
<td>0.999</td>
<td>0.917</td>
<td>1</td>
<td>0.729</td>
<td>5</td>
</tr>
<tr>
<td>rs7531118</td>
<td>1</td>
<td>72837239</td>
<td>-</td>
<td>0.74</td>
<td>0.949</td>
<td>0.963</td>
<td>0.785</td>
<td>1</td>
<td>0.858</td>
<td>0.973</td>
<td>0.921</td>
<td>5</td>
</tr>
<tr>
<td>rs9787523</td>
<td>10</td>
<td>106460460</td>
<td>SORCS3(g)</td>
<td>0.944</td>
<td>0.855</td>
<td>0.972</td>
<td>0.877</td>
<td>1</td>
<td>0.853</td>
<td>0.999</td>
<td>0.963</td>
<td>5</td>
</tr>
<tr>
<td>rs10265001</td>
<td>7</td>
<td>140665521</td>
<td>-</td>
<td>0.716</td>
<td>0.772</td>
<td>0.986</td>
<td>0.999</td>
<td>0.783</td>
<td>0.921</td>
<td>0.988</td>
<td>0.692</td>
<td>4</td>
</tr>
<tr>
<td>rs11688767</td>
<td>2</td>
<td>57988194</td>
<td>BCL11A(h)</td>
<td>0.845</td>
<td>0.899</td>
<td>0.929</td>
<td>0.983</td>
<td>1</td>
<td>0.849</td>
<td>1</td>
<td>0.698</td>
<td>4</td>
</tr>
<tr>
<td>rs12129573</td>
<td>1</td>
<td>73768366</td>
<td>-</td>
<td>0.929</td>
<td>0.835</td>
<td>0.894</td>
<td>0.948</td>
<td>1</td>
<td>0.85</td>
<td>1</td>
<td>0.539</td>
<td>4</td>
</tr>
</tbody>
</table>
SNP ID, location, prioritized candidate gene, disorder-specific m-values for 23 most pleiotropic loci. The number of disorders with high confidence association (m-values $\geq 0.9$) is shown in the last column. Evidence for candidate gene mapping include: g (genic SNP); q (brain cis-eQTLs); h (hi-C interacting gene based on FUMA); hf (hi-C-based interaction between associated SNP and target gene in the fetal brain from Won et al. 2016); ha (hi-C-based interaction in the adult brain from Wang et al. 2018); and tss (transcription start sites).

Of the 109 risk loci with shared effects, the 18q21.2 region surrounding SNP rs8084351 at the netrin 1 receptor gene $DCC$ featured the most pleiotropic association ($P_{\text{meta}} = 4.26 \times 10^{-12}$; Fig. 3a). This region showed association with all eight psychiatric disorders, and has been previously associated with both MD and neuroticism (Turley et al., 2018; Wray et al., 2018). The product of $DCC$ plays a key role in guiding axonal growth during neurodevelopment and serves as a master regulator of midline crossing and white matter projections (Bendriem and Ross, 2017). Gene expression data indicate that $DCC$ expression peaks during early prenatal development (Supplementary Fig. 4a).
Figure 3. Profile of disorder associations for illustrative pleiotropic loci: (A) rs8084351 on 18q21.2; (B) rs7193263 on 16p13.3; (C) rs117956829 on 11q14.3; and (D) rs10265001 on 7q34. For each locus, disorder-specific effects of the index SNP are shown using ForestPMPlot. The first panel is the forest plot, displaying disorder-specific association p-value, log odds ratios (ORs), and standard errors of the SNP. The meta-analysis p-value and the corresponding summary statistic are displayed on the top and the bottom of the forest plot, respectively. The second panel is the PM-plot in which X-axis represents the m-value, the posterior probability that the effect exists in each disorder, and the Y-axis represents the disorder-specific association p-value as -log_{10}(p-value). Disorders are depicted as a dot whose size represents the sample size of individual GWAS. Disorders with estimated m-values of at least 0.9 are colored in red, while those with m-values less than 0.9 are marked in green.

The second most pleiotropic locus in our analysis was identified in an intron of RBFOX1 (RNA Binding Fox-1 Homolog 1) on 16p13.3 (lead SNP rs7193263; $P_{meta} = 5.59 \times 10^{-11}$). The lead SNP showed association with all of the disorders except AN (Fig. 3b). RBFOX1 (also called A2BP1) encodes a splicing regulator mainly expressed in neurons and known to target several genes important to neuronal development, including NMDA receptor 1 and voltage-gated calcium channels (Hamada et al., 2015). Knock-down and silencing of RBFOX1 during mouse corticogenesis impairs neuronal migration and synapse formation (Hamada et al., 2015; Hamada et al., 2016), implying its pivotal role in early cortical maturation. In contrast to DCC, however, developmental gene-expression of RBFOX1 showed gradually increasing gene expression throughout the prenatal period (Supplementary Fig. 4b). Animal models and association studies have implicated RBFOX1 in aggressive behaviors, a trait observed in several of the disorders in our analysis (Fernandez-Castillo et al., 2017).

Of the 109 pleiotropic loci, 76 were identified in the GWAS of individual disorders, while the remaining 33 are novel. The most pleiotropic among these novel loci was a region downstream of NOX4 (NADPH Oxidase 4) that was associated with SCZ, BIP, MD, ASD, and AN (rs117956829; $P_{meta} = 1.82 \times 10^{-9}$; Fig. 3c). Brain Hi-C data (Wang et al., 2018; Won et al., 2016) detected a direct interaction of the cross-disorder association region with NOX4 in both adult and fetal brain (interaction $p=3.2\times10^{-16}$ and $9.324\times10^{-5}$, respectively). As a member of the family of NOX genes that encode subunits of NADPH oxidase, NOX4 is a major source of superoxide production in human brain and a promoter of neural stem cell growth (Kuroda et al., 2014; Topchiy et al., 2013).

Figure 3d illustrates another novel psychiatric risk locus associated with SCZ, BIP, ASD, and OCD ($P_{meta} = 3.58 \times 10^{-8}$). The lead SNP rs10265001 resides between MRPS33 (Mitochondrial Ribosomal Protein S33) and BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) on 7q34. The brain Hi-C data indicated interaction of the associated region with the promoters of two nearby genes: BRAF, which contributes to the MAP kinase signal transduction pathway and plays a role in postsynaptic responses of hippocampal neurons (Grantyn and Grantyn, 1973), and KDM7A (encoding Lysine Demethylase 7A), which plays a central role in the nervous system and midbrain development (Horton et al., 2010; Qi et al., 2010; Tsukada et al., 2010).
Our prior cross-disorder meta-analysis of five psychiatric disorders (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013) found no evidence of SNPs with antagonistic effects on two or more disorders. Here, we examined whether any variants with meta-analysis $p \leq 1 \times 10^{-6}$ had opposite directional effects between disorders (Methods). After adjusting for having examined 206 loci across eight disorders ($q < 0.001$), we identified 11 loci with evidence of opposite directional effects on two or more disorders (Fig. 4; Supplementary Table. 6). The disorder configuration of opposite directional effects varied for the 11 loci, including three loci with opposite directional effects on SCZ and MD (rs301805, rs1933802, rs3806843), two loci between SCZ and ASD (rs9329221, rs2921036), and one locus (rs75595651) with opposite directional effects on the two mood disorders, BIP and MD. Notably, all of the six loci involving SCZ and BIP exhibited the same directional effect on the two disorders ($P_{\text{binom}} < 0.05$), in line with their strong genome-wide genetic correlation.
Figure 4. Eleven loci with opposite directional effects. The radius of each wedge corresponds to the absolute values of the Z-scores (log(Odds ratios)/S.E) obtained from association tests of the SNP for eight disorders. The color indicates whether the examined SNP carries risk (red) or protective effects (green) for each disorder. The dotted line around the center indicates statistically significant SNP effects that account for multiple testing of 206 SNPs with the q-value of 0.001.

Functional characterization of pleiotropic risk loci

We conducted a series of bioinformatic analyses that examined whether loci with shared risk effects on multiple neuropsychiatric disorders had characteristic features that distinguished them from non-pleiotropic risk loci. First, we annotated the functional characteristics of 146 lead SNPs using various public data sources (Methods; Supplementary Table 7-9). Overall, they showed significant enrichment of genes expressed in the brain ($\beta$=0.123, SE=0.0109, enrichment $p = 1.22\times10^{-29}$) and pituitary ($\beta$=0.0916, SE=0.0136, $p = 8.74 \times 10^{-12}$), but not in the other Genotype-Tissue Expression (GTEx) tissues. (Supplementary Table 10; Fig. 5a). A separate analysis of 109 pleiotropic risk loci also showed specific enrichment of genes expressed in multiple brain tissues ($p = 1.55 \times 10^{-5}$; Supplementary Table 11), while disorder-specific loci showed nominally enriched brain gene expression in the cortex ($p = 2.14 \times 10^{-2}$; Supplementary Table 12).

Gene-set enrichment analyses using Gene Ontology data suggested involvement of pleiotropic risk loci in neurodevelopmental processes (Supplementary Table 13,14). The 109 pleiotropic risk loci were enriched for genes involved in neurogenesis (gene-set enrichment $p = 9.67 \times 10^{-6}$), regulation of nervous system development ($p = 3.41 \times 10^{-5}$), and neuron differentiation ($p = 3.30 \times 10^{-5}$), while enrichment of these gene-sets was not seen for disorder-specific risk loci (adjusted enrichment $p > 0.05$). Pleiotropic risk loci also showed enrichment of genes involved in specific neurotransmitter-related pathways -- glutamate receptor signaling ($p = 2.45 \times 10^{-6}$) and voltage-gated calcium channel complex ($p = 5.72 \times 10^{-4}$) -- while non-pleiotropic risk loci, which were predominantly SCZ-associated, were over-represented among acetylcholine receptor genes ($p = 7.25 \times 10^{-8}$). Analysis of cortical gene expression data also suggested enrichment of pleiotropic risk genes in cortical glutamatergic neurons through layers 2-6 (Supplementary Table 15), further supporting the shared role of glutamate receptor signaling in the pathogenesis of diverse neuropsychiatric disorders.
Figure 5. Results of functional genomics data analysis for pleiotropic vs. disorder-specific loci. (A) GTEX tissue-specific enrichment results for 146 risk loci associated with at least one of eight neuropsychiatric disorders. GTEX tissues were classified as 9 distinct categories, of which the brain tissues were colored in blue. The dotted red line indicates a statistically significant p-value after conducting Bonferroni correction for multiple testing. Psychiatric disorder-associated loci show significant enrichment in genes expressed in pituitary and all brain tissues except nerve_tibial. (B) Brain developmental expression trajectory displayed for the three groups of genes based on Kang et al. The 146 genome-wide significant loci from the cross-disorder meta analysis were clustered into three groups based on predicted disorder-specific associations: (1) no-pleiotropy; (2) pleiotropy=2; and (3) pleiotropy>2. The “no-pleiotropy” group included 37 loci that showed a single-disorder-specific association, while the “pleiotropy=2” and “pleiotropy>2” groups included 60 and 49 loci that were associated with two and more than two disorders, respectively. (C) In the adult cortex, genes mapped to pleiotropic loci were enriched for frontal cortex specific genes, while genes mapped to non-pleiotropic loci are enriched for occipital cortex specific genes. (D) Genes mapped to 146 risk loci show higher expression values in neurons and oligodendrocytes, with much higher neuronal specificity for pleiotropic loci.

In contrast to the differences in neuronal development and neuronal signaling pathways, pleiotropic and non-pleiotropic risk loci shared several characteristics related to genomic function. For instance, gene-set enrichment analyses indicated that both pleiotropic and non-pleiotropic risk loci were enriched for genes involved in the regulation of synaptic plasticity, neurotransmission, and synaptic cellular components. More than 41% of the genes associated with our genome-wide significant loci, both pleiotropic and non-
pleiotropic, were intolerant of loss of function mutations (pLI score ≥ 0.9); this is highly unlikely to occur by chance (Fisher’s exact $p=4.90\times10^{-8}$). This finding was consistent when examining pleiotropic ($p=2.85\times10^{-11}$) and non-pleiotropic risk loci ($p=1.56\times10^{-3}$) separately.

Next, we compared spatio-temporal gene-expression patterns for the 109 pleiotropic risk loci and the 37 disorder-specific loci using post-mortem brain data. On average, disorder-specific and pleiotropic risk loci showed a similar level of gene expression in both prenatal and postnatal development after multiple testing correction (t-test $p > 0.025\times10^{-2}$; Supplementary Fig. 5). During prenatal development, non-pleiotropic loci (mainly SCZ-associated) showed peak expression in the first trimester, after which expression rapidly decreased, while pleiotropic genes associated with only 2 disorders ("pleiotropy=2"; 60 loci) and those associated with more than 2 ("pleiotropy>2", 49 loci) showed peak expression around the second trimester (Fig. 5b). After birth, all three groups showed gradually increasing gene expression until adulthood. Expression levels were associated with the degree of pleiotropy, with the pleiotropy>2 group showing higher gene expression than either the pleiotropy=2 group (t-test $p < 2.10\times10^{-4}$) or non-pleiotropic risk loci (t-test $p < 2.2\times10^{-16}$).

Enrichment analyses using the genes preferentially expressed in specific cortical regions suggested that pleiotropic loci were over-represented among genes expressed in the frontal cortex, while non-pleiotropic loci were enriched in the occipital cortex (FDR $q<0.05$; Fig. 5c). Cell-type-specific analysis indicated that genes implicated in pleiotropic loci were mainly expressed in neurons (FDR $q<0.05$) but not in glial cell types. Further, enrichment of pleiotropic loci in neuronal cells was also associated with the degree of pleiotropy, as highlighted in Fig. 5d.

Previous studies of model organisms using gene knock-out experiments suggested that pleiotropic risk loci may undergo stronger selection than non-pleiotropic loci (Hill and Zhang, 2012). However, we found no evidence that pleiotropic risk variants are under stronger evolutionary constraints (Supplementary Table 16). Various comparative genomics resources, including PhyloP (Pollard et al., 2010), PhastCons (Siepel et al., 2005), and GERP++ (Davydov et al., 2010), showed our top loci to have similar properties regardless of the extent of pleiotropy. Neither did we find differences between disorder-specific lead SNPs and pleiotropic SNPs with respect to their minor allele frequencies, average heterozygosity, or predicted allele ages (Kiezun et al., 2013). Pleiotropic and non-pleiotropic SNPs also did not differ in terms of the distance to nearest genes, distance to splicing sites, chromosome compositions, and predicted functional consequences of non-coding regulatory elements.
**Relationship between cross-disorder genetic risk and other brain-related traits and diseases**

To explore the genetic relationship of cross-disorder genetic risk with other traits, we treated this 8-disorder GWAS meta-analysis as a single “cross-disorder phenotype.” We applied LDSC to estimate SNP heritability ($h^2_{SNP}$) and genetic correlations with other phenotypes, using block jackknife-based standard errors to estimate statistical significance. The estimated $h^2_{SNP}$ of the cross-disorder phenotype was 0.146 (SE 0.0058; observed scale). Using data for 28 brain-related traits selected from LDHub (Zheng et al., 2017), we found significant genetic correlations of the cross-disorder phenotype with seven traits (at a Bonferroni-corrected p-value threshold 0.002): never/ever smoking status, years of education, neuroticism, subjective well-being, and three sleep-related phenotypes (chronotype, insomnia, and excessive daytime sleepiness) (Supplementary Table 17).

GWAS catalog data for the 109 pleiotropic risk loci showed enrichment of implicated genes in a range of brain-related traits (Supplementary Table 18). As expected, the associated traits included previous studies of neuropsychiatric disorders including SCZ, BIP, and ASD. In addition, the pleiotropic risk loci were enriched among genes previously associated with neuroticism (corrected enrichment $p = 5.28 \times 10^{-6}$; *GRK3, CTNND1, DRD2, RGS6, RBOX1, ZNF804A, L3MBTL2, CHADL, RANGAP1, RSRC1, GMR3*), cognitive ability (corrected $p = 7.15 \times 10^{-5}$; *PTPRF, NEGR1, ELOVL3, SORCS3, DCC, CACNA1I*), and night sleep phenotypes (corrected $p = 1.86 \times 10^{-2}$; *PBX1, NPAS3, RGS6, GRIN2A, MYO18A, TIAF1, CNTN4, PPP2R2B, TENM2, CSMD1*). We also found significant enrichment of pleiotropic risk genes in multiple measures of body mass index (BMI), supporting previous studies suggesting a shared etiologic basis between a range of neuropsychiatric disorders and obesity (Hartwig et al., 2016; Lopresti and Drummond, 2013; Milaneschi et al., 2018).

**DISCUSSION**

In the largest cross-disorder GWAS meta-analysis of neuropsychiatric disorders to date, comprising more than 725,000 cases and controls across eight disorders, we identified 146 LD-independent lead SNPs associated with at least one disorder, including 35 novel loci. Of these, 109 loci were found to affect two or more disorders, although characterization of this pleiotropy is partly dependent on per-disorder sample size. Our results provide four major insights into the shared genetic basis of psychiatric disorders.

First, modeling of genetic correlations among the eight disorders using two different methods (EFA and hierarchical clustering) identified three groups of disorders based on shared genomics: one comprising disorders characterized by compulsive behaviors (AN, OCD and TS), a second comprising mood and psychotic disorders (MD, BIP and...
SCZ), and a third comprising two early-onset neurodevelopmental disorders (ASD and ADHD) and one disorder each from the first two factors (TS and MD). The loading of MD on two factors may reflect biological heterogeneity within MD, consistent with recent evidence showing that early-onset depression is associated with genetic risk for ADHD and with neurodevelopmental phenotypes (Rice et al., 2018). Overall, these results indicate a substantial pairwise genetic correlation between multiple disorders along with a higher-level genetic structure that point to broader domains underlying genetic risk to psychopathology. These findings are at odds with the classical, categorical classification of mental illness.

Second, variant-level analyses support the existence of substantial pleiotropy, with nearly 75% of the 146 genome-wide significant SNPs influencing more than one of the eight examined disorders. We also identified a set of 23 loci with particularly extensive pleiotropic profiles, affecting four or more disorders. The most highly pleiotropic locus in our analyses, with evidence of association with all eight disorders, maps within DCC, a gene fundamental to the early development of white matter connections in the brain (Bendriem and Ross, 2017). Prior studies showed that DCC is a master regulator of axon guidance (through its interactions with netrin-1 and draxin (Liu et al., 2018). Loss of function mutations in DCC cause severe neurodevelopmental syndromes involving loss of midline commissural tracts and diffuse disorganization of white matter tracts (Bendriem and Ross, 2017; Jamuar et al., 2017; Marsh et al., 2017). A highly pleiotropic effect of variation in DCC on diverse psychiatric disorders with childhood and adolescent onset would be consistent with its role in both early organization of neuronal circuits and the maturation of mesolimbic dopaminergic connections to the prefrontal cortex during adolescence (Hoops and Flores, 2017; Reynolds et al., 2018; Vosberg et al., 2018).

We also identified a set of loci that have opposite effects on risk of psychiatric disorders. Notably, these included loci with opposing effects on pairs of disorders that are genetically correlated and have common clinical features. For example, a SNP within MRSA was associated with opposing effects on two neurodevelopmental disorders (ASD and SCZ), and a variant within KIAA1109 had opposite directional effects on major mood disorders (BIP and MD) (Supplementary Table 6). These results underscore the complexity of genetic relationships among related disorders and suggest that overall genetic correlations may obscure antagonistic biological mechanisms that operate at the level of component loci and pathways as seen in immune-mediated diseases (Baurecht et al., 2015; Lettre and Rioux, 2008; Schmitt et al., 2016). This heterogeneity of effects between genetically correlated disorders is also consistent with a recent analysis that revealed loci contributing to biological differences between BIP and SCZ and found polygenic risk score associations with specific symptom dimensions (Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018).
Third, we found extensive evidence that neurodevelopmental effects underlie the cross-disorder genetics of mental illness. In addition to *DCC*, a link between pleiotropy and genetic effects on neurodevelopment was also seen for other top loci in our analysis, including *RBFOX1*, *BRAF*, and *KDM7A*, all of which have been shown in prior research to influence aspects of nervous system development. Gene enrichment analyses showed that pleiotropic loci were distinguished from disorder-specific loci by their involvement in neurodevelopmental pathways including neurogenesis, regulation of nervous system development, and neuron differentiation. These results are consistent with those of a smaller recent analysis in the population-based Danish iPSYCH cohort (comprising 46,008 cases and 19,526 controls across six neuropsychiatric disorders) (Schork et al., 2017). In that analysis, consistent with the present findings, functional genomic characterization of cross-disorder loci implicated fetal neurodevelopmental processes, with greater prenatal than postnatal expression. However, the specific loci, cell types, and pathways implicated in the iPSYCH analysis differed from those identified in our study. Of note, however, *SORCS3* emerged as a genome-wide significant cross-disorder locus in both studies.

Fourth, our analyses of spatiotemporal gene expression profiles revealed that pleiotropic loci are enriched among genes expressed in neuronal cell types, particularly in frontal or prefrontal regions. They also demonstrated a distinctive feature of genes related to pleiotropic loci: compared with disorder-specific loci, they are on average expressed at higher levels both prenatally and postnatally (Figure 4). More specifically, single-disorder (mainly SCZ) loci were related to genes that were preferentially expressed in the first fetal trimester followed by a decline over the prenatal period and then relatively stable levels postnatally. In contrast, expression of genes related to pleiotropic loci peaked in the second trimester and remained overexpressed throughout the lifespan. When dividing the pleiotropic loci into bins of those associated with two disorders (mainly SCZ and BIP) vs. three or more disorders, we observed a consistent gradient of greater expression associated with broader pleiotropy.

Taken together, our results suggest that pleiotropic loci appear to be distinguished by both their differential importance in neurodevelopmental processes and their heightened brain expression after the first trimester. Apart from this, however, pleiotropic loci were similar to non-pleiotropic loci across a range of other functional features, including intolerance to loss-of-function mutations, evidence of selection, minor allele frequencies, and genomic position relative to functional elements.

Overall, our results identify a range of pleiotropic effects among loci associated with psychiatric disorders. Consistent with prior research (Brainstorm Consortium, 2018; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), we found substantial pairwise genetic correlations across child- and adult-onset disorders and
extended these findings by demonstrating clusters of genetically-related disorders. These results augment a substantial body of research demonstrating that genetic influences on psychopathology do not map cleanly onto the clinical nosology instantiated in the DSM or ICD (Smoller et al., 2018). Using a range of bioinformatic and functional genomic analyses, we find that loci with pleiotropic effects are distinguished by their involvement in early neurodevelopment and increased expression beginning in the second trimester of fetal development and persisting throughout adulthood. Taken together, the analyses presented here suggest that genetic influences on psychiatric disorders comprise at least two general classes of loci. The first comprises a set of genes that confer relatively broad liability to psychiatric disorders by acting on early neurodevelopment and the establishment of brain circuitry. These pleiotropic genes begin to come online by the second trimester of fetal development and exhibit differentially high expression thereafter. Such loci may underlie a latent general psychopathology factor (the “p” factor) (Caspi et al., 2014) that has been identified in developmental studies of mental disorders, comprising transdiagnostic symptom clusters (internalizing, externalizing, and psychotic) (Caspi et al., 2014). The expression and differentiation of this generalized genetic risk into discrete psychiatric syndromes (e.g., ASD, BIP, AN) may then involve direct and/or interactive effects of additional sets of loci and environmental factors, possibly mediated by epigenetic effects, that shape phenotypic expression via effects on brain structure/function and behavior. Further research will be needed to clarify the nature of such effects.

Our results should be interpreted in light of several limitations. First, while our dataset is the largest genome-wide cross-disorder analysis to date, data available for individual disorders varied substantially—from a minimum of 9,725 cases and controls for OCD to 461,134 cases and controls for MD. This imbalance of sample size may have limited our power to detect pleiotropic effects on underrepresented disorders. Second, it is possible that comorbidity among disorders contributed to apparent pleiotropy; however we found that less than 2% of cases overlapped between disorder datasets (excluding 23andMe data) and we adjusted for overlap in meta-analysis. Third, the method we applied to detect cross-phenotype association, which combines an all-subsets fixed-effects GWAS meta-analysis with a Bayesian method for evaluating the best-fit configuration of genotype-phenotype associations, is one of several approaches (Solovieff et al., 2013). However, we have previously shown that this method outperforms a range of alternatives for detecting pleiotropy under various settings (Zhu et al., 2018). Fourth, our designation of loci as pleiotropic vs. non-pleiotropic loci refers only to their observed effects on the eight target brain disorders. Thus, some of the “non-pleiotropic” loci may have additional effects on psychiatric phenotypes that were not included in our meta-analysis and/or on non-psychiatric phenotypes. Fifth, our functional genomic analyses were constrained by the limitations of existing resources (e.g. spatiotemporal gene expression data resources). Our work underscores the need for more comprehensive functional data including single cell transcriptomic and epigenomic profiles across
development and brain tissues. Lastly, we included only individuals of European ancestry to avoid potential confounding due to ancestral heterogeneity across distinct disorder studies. Similar efforts are needed to examine these questions in other populations.

In sum, in a large-scale cross-disorder genome-wide meta-analysis, we identified three genetic factors underlying the genetic basis of eight psychiatric disorders. We also identified 109 genomic loci with pleiotropic effects, of which 33 have not previously been associated with any of the individual disorders. In addition, we identified 11 loci with opposing directional effects on two or more psychiatric disorders. These results highlight disparities between our clinically-defined classification of psychiatric disorders and underlying biology. Future research is warranted to determine whether more genetically-defined influences on cross-diagnostic traits or subtypes of dissect may inform a biologically-informed reconceptualization of psychiatric nosology. Finally, we found that genes associated with multiple psychiatric disorders are disproportionately associated with biological pathways related to neurodevelopment and exhibit distinctive gene expression patterns, with enhanced expression beginning in the second prenatal trimester and persistently elevated expression relative to less pleiotropic genes. Therapeutic modulation of pleiotropic gene products could have broad-spectrum effects on psychopathology.

1, Psychiatric and Neurodevelopmental Genetics Unit (PNGU) and the Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
2, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
3, Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
4, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
5, UNC Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599, USA
6, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
7, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
8, Department of Psychology, University of Texas at Austin, Austin, TX USA
9, Department of Psychiatry, and Population Research Center, University of Texas at Austin, Austin, TX USA
10, Vrije Universiteit Amsterdam, Dept of Biological Psychology & EMGO+ Institute for Health and Care Research, Amsterdam, NL
11, Charite Universitätsmedizin Berlin, Berlin, Germany
12, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
13, Icahn School of Medicine at Mount Sinai, New York, NY, USA
14, Broad Institute of MIT and Harvard, Cambridge, USA
15, Department Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, VU University, Amsterdam, The Netherlands
16, Department Clinical Genetics, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands
17, Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
18, Department of Biomedicine, Aarhus University, Aarhus, Denmark
19, Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
20, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
21, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, US
22, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
23. Interdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
24. Department of Psychiatry, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
25. Veterans Integrated Service Network (VISN4) Mental Illness Research, Education, and Clinical Center (MIRECC), Crescenz VA Medical Center, Philadelphia, PA, USA
26. Department of Public Health, University of Helsinki, Helsinki, Finland
27. Department of Clinical Sciences, Psychiatry, Umeå University Medical Faculty, Umeå, SE
28. Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA
29. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, GB
30. Departments of Human Genetics (855) and Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
31. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada
32. Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
33. Department of Psychiatry, Faculty of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
34. ADHD Outpatient Clinic, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
35. The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark
36. Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark
37. Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark
38. Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
39. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
40. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
41. MRC Centre for Neuropsychiatric Genetics & Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom
42. National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark
43. Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark
44. Department of Child and Adolescent Psychiatry, National University Hospital, Reykjavik, Iceland
45. Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
46. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
47. 23andMe, Mountain View, California, USA
48. QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia
49. Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
50. deCODE genetics/Amgen, Reykjavik, Iceland
51. Faculty of Medicine, University of Iceland, Reykjavik, Iceland
52. Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark
53. Psychiatry, Neurosciences and Mental Health, The Hospital for Sick Children, University of Toronto, Toronto, Canada
54. Department of Biological Psychology, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands
55. Departments of Human Genetics (855) and Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
56, Department of Psychiatry, Genetics, and Neuroscience, Yale University School of Medicine, New Haven, Connecticut, USA
57, Veterans Affairs Connecticut Healthcare Center, West Haven, Connecticut, USA
58, The Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
59, Division of Molecular Psychiatry, Clinical Research Unit on Disorders of Neuropsychiatric and Developmental Disorders, Laboratory of Translational Neuroscience, Center of Mental Health, University of Wuerzburg, Germany
60, Department of Neuroscience, School for Mental Health and Neuroscience (MHENS), Maastricht University, The Netherlands
61, Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
62, Child Health Research Centre, University of Queensland, Brisbane Australia
63, Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, Brisbane, Australia
64, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Frankfurt am Main, DE
65, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
66, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
67, Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark
68, Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
69, NORMENT - KG Jebsen Centre for Psychosis Research, University of Oslo, Oslo, Norway
70, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
71, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA
72, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
73, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
74, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
75, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
76, NevSom, Department of Rare Disorders and Disabilities, Oslo University Hospital, Norway
77, Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands
78, MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
79, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands
80, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
81, Computational Biology Department, Carnegie Mellon University, Pittsburgh, PA, USA
82, Department of Statistics and Data Science, Carnegie Mellon University, Pittsburgh, PA, USA
83, The State Diagnostic and Counselling Centre, Digranesvegur 5, Kópavogur, Iceland
84, deCODE genetics/Amgen, Sturlugata 8, Reykjavik, Iceland
85, Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA
86, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
87, Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA
88, Inst. Human Genetics, University of California San Francisco, San Francisco, CA, USA
89, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA
90, Department for Congenital Disorders, Center for Neonatal Screening, Statens Serum Institut, Copenhagen, Denmark
91, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
92, FondaMental Foundation, Crétteil, France
93, Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
94, Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, CG, The Netherlands
95, Department of Child and Adolescent Psychiatry, Robert Debré Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
96, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
97, Department of Psychiatry, University of Utah, Salt Lake City, UT, USA
98, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
99, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
100, Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
101, Maine Medical Center Research Institute, Portland, ME, USA
102, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
103, Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB
104, NIHR Maudsley Biomedical Research Centre, King's College London, London, GB
105, Department of Biomedicine, University of Basel, Basel, CH
106, Department of Psychiatry (UPK), University of Basel, Basel, CH
107, Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, DE
108, Centre for Human Genetics, University of Marburg, Marburg, DE
109, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, CH
110, Division of Psychiatry, University College London, London, GB
111, Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, SE
112, Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen, DK
113, Institute of Clinical Medicine, University of Oslo, Oslo, NO
114, deCODE Genetics / Amgen, Reykjavik, IS
115, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, AU
116, QIMR Berghofer Medical Research Institute, Brisbane, Australia
117, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
118, Queensland Brain Institute, University of Queensland, Brisbane, Australia
119, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, AU
120, Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, US
121, NEUROSCIENCE, Istituto Di Ricerche Farmacologiche Mario Negri, Milano, IT
122, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, US
123, Psychiatry, Berkshire Healthcare NHS Foundation Trust, Bracknell, GB
124, Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, DE
125, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE
126, Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, NO
127, Human Genetics, University of California Los Angeles, Los Angeles, CA, US
128, Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, DE
129, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, US
130, Department of Psychiatry, University of California at San Francisco, San Francisco, California, 94143 USA
131, Division of Psychiatry, University of Edinburgh, Edinburgh, GB
132, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, DE
170. Psychiatry, Harvard Medical School, Boston, MA, US
171. Division of Clinical Research, Massachusetts General Hospital, Boston, MA, US
172. Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, ES
173. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, US
174. Neuroscience Research Australia, Sydney, NSW, AU
175. Faculty of Medicine, Department of Psychiatry, School of Health Sciences, University of Iceland, Reykjavik, IS
176. Div Mental Health and Addiction, Oslo University Hospital, Oslo, NO
177. NORMENT, University of Oslo, Oslo, NO
178. Centre for Addiction and Mental Health, Toronto, ON, CA
179. Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, US
180. NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine and Diakonhjemmet Hospital, University of Oslo, Oslo, NO
181. National Institute of Mental Health, Klecany, CZ
182. Discipline of Psychiatry, University of Adelaide, Adelaide, SA, AU
183. Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, US
184. Department of Psychiatry, University of Münster, Münster, DE
185. School of Medical Sciences, University of New South Wales, Sydney, NSW, AU
186. Department of Human Genetics, University of Chicago, Chicago, IL, US
187. Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, RO
188. Department of Medical & Molecular Genetics, King's College London, London, GB
189. Cancer Epidemiology and Prevention, M. Sklodowska-Curie Institute – Oncology Center, Warsaw, PL
190. Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, GB
191. Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, US
192. Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NO
193. Division of Mental Health and Addiction, University of Oslo, Institute of Clinical Medicine, Oslo, NO
194. Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology - NTNU, Trondheim, NO
195. Psychiatry, St Olavs University Hospital, Trondheim, NO
196. Munich Cluster for Systems Neurology (SyNergy), Munich, DE
197. University of Liverpool, Liverpool, GB
198. Division of Psychiatry, Haukeland Universitetssjukehus, Bergen, NO
199. Faculty of Medicine and Dentistry, University of Bergen, Bergen, NO
200. Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, US
201. College of Medicine Institute for Genomic Health, SUNY Downstate Medical Center College of Medicine, Brooklyn, NY, US
202. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, IT
203. Department of Psychiatry, Hospital Namsos, Namsos, NO
204. Department of Neuroscience, Norges Teknisk Naturvitenskapelige Universitet Fakultet for naturvitenskap og teknologi, Trondheim, NO
205. Dept of Psychiatry, Sankt Olavs Hospital Universitetssykehuset i Trondheim, Trondheim, NO
206, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, ES
207, Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, US
208, Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
209, Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands
210, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
211, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
212, Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
213, Biopsychosocial Corporation, Vienna, Austria
214, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
215, First Faculty of Medicine, Institute of Hygiene and Epidemiology, Charles University, Prague, Czech Republic
216, BioRealm, LLC, Walnut, California, US
217, Oregon Research Institute, Eugene, Oregon, US
218, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
219, Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden
220, INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France
221, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
222, Department of Medical Biology, School of Medicine, University of Split, Split, Croatia
223, The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, US
224, Institute of Psychiatry, Psychology and Neuroscience, Social, Genetic and Developmental Psychiatry (SGDP) Centre, King’s College London, London, UK
225, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany
226, Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
227, Klinikum Frankfurt/Oder, Frankfurt, Germany
228, Medical University of Vienna, Vienna, Austria
229, Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy
230, Department of Emergency Psychiatry and Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France
231, Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, US
232, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
233, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
234, School of Social and Community Medicine, University of Bristol, Bristol, UK
235, Department of Neurosciences, University of Padova, Padova, Italy
236, College of Nursing, Seattle University, Seattle, Washington, US
237, Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, US
238, L’institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France
239, L’institut du thorax, CHU Nantes, Nantes, France
240, Barcelona Institute of Science and Technology, Barcelona, Spain
241, Universitat Pompeu Fabra, Barcelona, Spain
242, Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
243, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, Germany
244, Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
245, Department of Psychology, University of Oslo, Oslo University Hospital, Oslo, Norway
246, Department of Psychiatry, University Hospital of Bellvitge –IDIBELL and CIBERobn, Barcelona, Spain
247, Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
248, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany
249, Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany
250, Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
251, Department of Cancer, Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
252, Division of Nephrology and Dialysis, Institute of Internal Medicine and Medical Specialties, Columbus-Gemelli University Hospital, Rome, Italy
253, Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany
254, 1st Psychiatric Department, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece
255, CMME (Groupe Hospitalier Sainte-Anne), Paris Descartes University, Paris, France
256, Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, US
257, Department of Psychiatry, Weill Cornell Medical College, New York, New York, US
258, Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany
259, Eating Recovery Center, Denver, Colorado, US
260, Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
261, Canterbury District Health Board, Christchurch, New Zealand
262, Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
263, Department of Psychiatry, First Faculty of Medicine, Charles University, Prague, Czech Republic
264, Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
265, Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria
266, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands
267, Department of Psychiatry, University of California San Diego, San Diego, California, US
268, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
269, Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, Korea
270, Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
271, Department of Psychology, Michigan State University, East Lansing, Michigan, US
272, Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway
273, Department of Clinical Science, K.G. Jebsen Centre for Psychosis Research, Norwegian Centre for Mental Disorders Research (NORMENT), University of Bergen, Bergen, Norway
274, Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
275, Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, Bergen, Norway
276, Institute of Medical Science, University of Toronto, Toronto, Canada
277, Department of Psychiatry, University of Campania Luigi Vanvitelli , Naples, Italy
278, Department of Psychiatry, University College Cork, Cork, Ireland
279, Eist Linn Adolescent Unit, Bessborough, Health Service Executive South, Cork, Ireland
280, Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, US
281, National Center for PTSD, VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, US
282, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy
283, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy
284, Kartini Clinic, Portland, Oregon, US
285, Saint Joan de Déu Research Institute, Saint Joan de Déu Barcelona Children’s Hospital, Barcelona, Spain
286, Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
287, Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain
288, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
289, Department of Health Science, University of Florence, Florence, Italy
290, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
291, Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany
292, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
293, Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University, Prague, Czech Republic
294, Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands
295, Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
296, Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
297, IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
298, Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US
299, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, US
300, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
301, Department of Psychiatry, University of Naples SUN, Naples, Italy
302, Department of Psychiatry, University of Perugia, Perugia, Italy
303, Brain Sciences Department, Stremble Ventures, Limassol, Cyprus
304, Pediatric Intensive Care Unit, P. & A. Kyriakou Children’s Hospital, University of Athens, Athens, Greece
305, Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, The Netherlands
306, School of Psychology, Flinders University, Adelaide, Australia
307, School of Psychology, Curtin University, Perth, Australia
308, School of Paediatrics and Child Health, University of Western Australia, Perth, Australia
309, Helmholtz Centre Munich - German Research Center for Environmental Health, Munich, Germany
310, Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Canada
311, Toronto General Hospital, Toronto, Canada
312, Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany
313, Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany
314, University of Edinburgh, Division of Psychiatry, Edinburgh, GB
315, Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry, Munich, DE
316, Virginia Commonwealth University, Department of Psychiatry, Richmond, VA, US
317, Vrije Universiteit Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, NL
318, Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA, US
319, Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, SE
320, University Hospital of Lausanne, Department of Psychiatry, Prilly, Vaud, CH
321, QIMR Berghofer Medical Research Institute, Genetics and Computational Biology, Brisbane, QLD, AU
322, Erasmus MC, Epidemiology, Rotterdam, Zuid-Holland, NL
323, Dokuz Eylül University School Of Medicine, Psychiatry, Izmir, TR
324, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Department of Genetic Epidemiology in Psychiatry, Mannheim, Baden-Württemberg, DE
325, F. Hoffmann-La Roche Ltd, Roche Product Development, Basel, CH
326, Kaiser Permanente Northern California, Division of Research, Oakland, CA, US
327, Columbia University College of Physicians and Surgeons, Psychiatry, New York, NY, US
328, University of British Columbia, Medical Genetics, Vancouver, BC, CA
329, University of British Columbia, Statistics, Vancouver, BC, CA
330, Virginia Commonwealth University, Virginia Institute for Psychiatric & Behavioral Genetics, Richmond, VA, US
331, Solid Biosciences , Boston, MA, US
332, Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, DE
333, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, US
334, University of Glasgow, Institute of Health and Wellbeing, Glasgow, GB
335, University of Münster, Institute of Epidemiology and Social Medicine, Münster, Nordrhein-Westfalen, DE
336, University of Edinburgh, Medical Genetics Section, CGEM, IGMM, Edinburgh, GB
337, University Medicine Greifswald, Department of Psychiatry and Psychotherapy, Greifswald, Mecklenburg-Vorpommern, DE
338, University of Melbourne, Department of Psychiatry, Melbourne Medical School, Melbourne, AU
339, Vrije Universiteit Medical Center, Amsterdam Public Health Institute, Amsterdam, NL
340, Università degli Studi di Trento, Centre for Integrative Biology , Trento, Trentino-Alto Adige, IT
341, Faculty of Medicine, University of Freiburg, Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg, DE
342, Kaiser Permanente Northern California, Psychiatry, San Francisco, CA, US
343, University of Toronto, Department of Psychiatry, Toronto, ON, CA
344, University College London, Division of Psychiatry, London, GB
345, Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, US
346, Erasmus MC, Child and Adolescent Psychiatry, Rotterdam, Zuid-Holland, NL
347, Erasmus MC, Psychiatry, Rotterdam, Zuid-Holland, NL
348, Dalhousie University, Psychiatry, Halifax, NS, CA
349, New York State Psychiatric Institute, Division of Epidemiology, New York, NY, US
350, Stanford University, Psychiatry & Behavioral Sciences, Stanford, CA, US  
351, Krembil Research Institute, University Health Network, Toronto, Canada  
352, Hospital for Sick Children, Toronto, Canada  
353, University of Toronto, Toronto, Canada  
354, University of California, San Francisco, CA, USA  
355, University of Groningen, Groningen, the Netherlands  
356, Yale University School of Medicine, New Haven, CT, USA  
357, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA  
358, Centre National Maladie ‘Syndrome Rare Gilles de la Tourette’, Groupe Hospitalier Pitié-Salpêtrière, Paris, France  
359, Assistance Publique-Hôpitaux de Paris, Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France  
360, Sorbonne Universités, UPMC Université Paris 06, UMR S 1127, CNRS UMR 7225, ICM, Paris, France  
361, De Bascule, Amsterdam, The Netherlands  
362, Department of Child and Adolescent Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands  
363, Carver College of Medicine, University of Iowa, Iowa City, IA, USA  
364, Sección de Neuropediatría, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain  
365, Yulius Academy, Yulius Mental Health Organization, Barendrecht, The Netherlands  
366, Department of Psychiatry and UF Genetics Institute, University of Florida, Gainesville, FL, USA  
367, McKnight Brain Institute, University of Florida, Gainesville, FL, USA  
368, Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain  
369, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain  
370, Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA  
371, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA  
372, Division of Neuropsychiatry, University College London, London, UK  
373, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technischen Universität Dresden, Dresden, Germany  
374, Department of Psychiatry, University of Toronto, Toronto, Canada  
375, University Health Network, University of Toronto, Toronto, Canada  
376, Youthdale Treatment Centers, Toronto, Canada  
377, Department of Neurology, Admiraal De Ruyter Hospital, Goes, The Netherlands  
378, Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada  
379, Departments of Psychiatry and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Canada  
380, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, Canada  
381, Johns Hopkins University School of Medicine, Baltimore, MD, USA  
382, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA  
383, Clinical Research, Grupo Médico Carracci, Mexico City, Mexico  
384, MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, Cape Town, South Africa  
385, National Institute of Genomic Medicine (INMEGEN), Ciudad de México, Mexico  
386, Frederick W. Thompson Anxiety Disorders Centre, Sunnybrook Health Sciences Centre, Toronto, Canada  
387, Groote Schuur Hospital, Cape Town, South Africa
455, Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden
456, NORMENT, Institute of Clinical Medicine, Psychiatry section, University of Oslo, Norway
457, Department of Clinical and Experimental Medicine, Catania University, Italy
458, Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles
459, Center for Genomic Medicine and Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
460, Northwell Health, New York City, NY, USA
461, Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology, University of Oslo
462, NORMENT and KG Jebsen Center for neuropsychiatric disorders, Division of psychiatry, Haukeland University Hospital and Department of Clinical Medicine, University of Bergen, Norway
463, PRC for Health Behaviour, School of Medicine and Public Health, University of Newcastle, Callaghan NSW 2308, Australia
464, New York University (NYU) Langone Medical Center, New York City, NY, USA
465, University of Miami Health System, Miami, FL, USA
466, Hospital Clinic de Barcelona, Barcelona, Spain
467, Child and Adolescent Mental Health Center, Mental Health Services – Capital Region of Denmark, Denmark
468, Guy's and Saint Thomas' NHS Foundation Trust, King's College London, London, GB
469, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA
470, Columbia University, New York, NY, USA
471, Sarah Lawrence College, Bronxville, NY, USA
472, Boston University, Boston, MA, USA
473, Hallym University Suicide and School Mental Health Institute, Hallym University, Sacred Heart Hospital, Anyang, South Korea
474, Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea
475, National Health Insurance Corporation Ilsan Hospital, Goyang, South Korea
476, University of California Medical Center, San Francisco, CA, USA
477, Korea Institute for Children's Social Development, Seoul, Republic of Korea
478, University of Cologne, Cologne, Germany
479, Kangbuk Samsung Medical Center, Seoul, South Korea
480, Severance Hospital, Seoul, South Korea
481, Great Ormond Street Hospital For Children NHS Trust, King's College London, London, GB
482, University Hospital Schleswig-Holstein, University of Luebeck, Lübeck, Germany
483, Capital Region Psychiatry, University of Lausanne, Child and Adolescent Mental Health Centre Capital, Region, University of Copenhagen, Copenhagen, Denmark
484, Yonsei University College of Medicine, Seoul, South Korea
485, Catholic University of Korea, Seoul, South Korea
486, University of Luebeck, Lübeck, Germany
487, University of California San Diego, San Diego, CA, USA
488, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA
489, Baylor College of Medicine, Houston, TX, USA
490, CHU Sainte Justine, Neurology, University of Montreal, Canada
491, Universitat de Barcelona Facultat de Medicina, Barcelona, Spain
492, Medical School Hannover (MHH), Hannover, Germany
493, University of California Berkeley, Berkeley, CA, USA
494, Department of Child and Adolescent Psychiatry, Sorbonne Universités, Paris, France
495, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
496, University of Utah, Salt Lake City, UT, USA
AUTHOR CONTRIBUTIONS


Editorial Revisions Group: S.B., J.L., H.K., A.K., E.H.C., G.K., G.C., J.K., C.C.Z., P.J.H., T.B., L.A.R., B.F., J.I.N. The remaining authors contributed to the recruitment, genotyping, or data processing for the contributing components of the study. All other authors saw, had the opportunity to comment on, and approved the final draft.

ACKNOWLEDGMENTS

Full acknowledgements and a list of funding are in the Supplementary Note. The work of the contributing groups was supported by numerous grants from governmental and charitable bodies as well as philanthropic donation. Specifically, P.H.L. (R00MH101367) and J.W.S. (R01MH106547; R01MH117599; U01HG008685). We thank the research participants and employees of 23andMe, Inc. for their contribution to this study.

DECLARATIONS OF INTERESTS

J.W.S. is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe. HRK (Henry R. Kranzler) is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. HRK and JG (Joel Gelernter) are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. BMN (Benjamin M Neale) is a member of the Deep Genomics Scientific Advisory Board, a consultant for Camp4 Therapeutics Corporation, a consultant for Merck & Co., a consultant for Avanir Pharmaceuticals, Inc, and a consultant for Takeda Pharmaceutical. KMV (Kirsten Müller-Vahl) has nonfinancial competing interests as a member of the TAA medical advisory board, the scientific advisory board of the German Tourette Association TGD, the board of directors of the German (ACM) and the International (IACM) Association for Cannabinoid Medicines, and the committee of experts for narcotic drugs at the federal opium bureau of the Federal Institute for Drugs and Medical Devices (BfArM) in Germany; has received financial or material research support from the EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), the German Research Foundation (DFG: GZ MU 1527/3-1), the German Ministry of Education and
Research (BMBF: 01KG1421), the National Institute of Mental Health (NIMH), the Tourette Gesellschaft Deutschland e.V., the Else-Kroner-Fresenius-Stiftung, and GW, Almirall, Abide Therapeutics, and Therapix Biosiences; has served as a guest editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects”, is an associate editor for “Cannabis and Cannabinoid Research” and an Editorial Board Member of “Medical Cannabis and Cannabinoids”; has received consultant’s honoraria from Abide Therapeutics, Fundacion Canna, Therapix Biosiences and Wayland Group, speaker’s fees from Tilray, and royalties from Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and is a consultant for Zynerba Pharmaceuticals. JIN has been an investigator for Assurex and is currently an investigator for Janssen. BF has received educational speaking fees from Medice and Shire. The other authors declare no competing interests.
REFERENCES


Global Burden of Disease Injury Incidence Prevalence Collaborators (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328


determinants of Tourette syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry.


Supplementary Figure Titles and Legends

Figure S1. Hierarchical clustering of genetic architecture across eight neuropsychiatric disorders. (Related to Table S3) Hierarchical clustering revealed three sub-groups within the eight disorders. Results were very similar to those obtained using exploratory factor analysis and genomic structural equation modeling.

Figure S2. P-M plots for top 146 loci. (Related to Figure 3 and Table S5) M-values were generated for each locus for each disorder and indicate the presence or absence of a disorder-specific effect. M-values were plotted with the negative log odds of the corresponding p-values for each disorder for a given SNP; P-M plots were generated for each of the top 146 loci. Log odds ratios for the effect of the SNP on each disorder and a summary across disorders was also plotted. As expected, most of the top SNPs (109/146) were pleiotropic.

Figure S3. Statistical power and number of cross-disorder associations (Related to Table S4). Power to detect associations across pairs of disorders was plotted with the number of cross-disorder associations identified in the current meta-analysis. For each pair of disorders, power was estimated using the number of cases and heritability for each disorder, as well as the genetic correlation between the disorders. In general, as power increased, so did the number of SNPs identified.

Figure S4. Gene expression of top loci across development. (Related to Figure 3) Gene expression trajectories from a transcriptome atlas of post-mortem brain tissue across development are plotted for four top loci, DCC, RBFOX1, NOX4 and BRAF in six different brain tissue types. AMY = amygdala; MD = mediodorsal nucleus of the thalamus; CBC = cerebellar cortex; NCX = neocortex; HIP = hippocampus; STR = striatum.

Figure S5. Gene expression in the brain for pleiotropic and non-pleiotropic loci. (Related to Figure 5) Average normalized gene expression in fetal and adult post-mortem brain tissue for pleiotropic (109) and non-pleiotropic (37) loci were plotted. Disorder-specific and pleiotropic risk loci showed a similar level of gene expression in prenatal and postnatal development after multiple testing correction (t-test p > 0.025).
STAR* METHODS

CONTACT FOR REAGENT AND RESOURCE SHARING

Any inquiries about analytical results or other information should be directed to Phil H. Lee (plee0@mgh.harvard.edu) or Jordan W. Smoller (jsmoller@mgh.harvard.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Genotyped sample description
Genotype data from eight studies of genetic associations with psychiatric disorders conducted by the Psychiatric Genomics Consortium were included in this report. A summary of each study is provided below, however, detailed sample descriptions are available in the primary publication. The lead PI of every cohort included across studies certified that their protocol was approved by their local Ethical Committee.

Supplementary Table 1 lists for each disorder the number of cases and controls, the number of loci identified in the single disorder genome-wide association study, and SNP-based heritability.

Schizophrenia | Ripke et al., 2014
108 loci were identified as associated with schizophrenia in a case-control meta-analysis including 150,064 individuals. For the current study, the 46 case-control cohorts of European ancestry were retained, totaling 33,640 cases and 43,546 controls. Cases were defined as individuals diagnosed with schizophrenia or schizoaffective disorder, which was determined by research-based assessment or clinician diagnosis depending on the sample.

Bipolar disorder | Stahl et al., 2018
Thirty-two case-control cohorts from Europe, North America, and Australia including 20,352 cases and 31,358 controls of European ancestry were meta-analyzed to identify 30 loci associated with bipolar disorder. Cases met criteria for lifetime diagnosis of bipolar disorder as defined by DSM-IV, ICD-9, or ICD-10, which was established using interview-based structured assessment, clinician-administered checklists, or review of medical records. All subjects in the meta-analysis were included in the current study.

Major depression | Wray et al., 2018
Seven case-control cohorts were combined to identify 44 loci associated with major depression. The first cohort included 29 case-control samples of European descent where lifetime diagnosis of major depressive disorder was ascertained using structured clinical interviews (DSM-V, ICD-9, ICD-10), clinician-administered checklists,
or review of medical records. Six additional cohorts of European ancestry, including the Hyde et al study (23andMe, Inc), determined case status using other methods including national or hospital treatment registers, self-reported symptoms or treatment by a medical professional, or direct interviews. Analyses comparing the original cohort with the additional ones indicated strong correlation of common genetic variants and little evidence of heterogeneity. 130,664 cases and 330,470 controls from these cohorts were included in the current analyses.

Attention deficit hyperactive disorder | Demontis et al., 2019

Twelve cohorts of European, North American, and Chinese descent were aggregated in a meta-analysis of attention deficit and hyperactive disorder, revealing 12 associated loci. For the first cohort, cases were ascertained using the Danish Psychiatric Central Research Registrar and diagnoses were confirmed by psychiatrists according to ICD-10. The remaining studies included four parent-offspring trio cohorts and seven case-control cohorts. Cases were recruited from clinics, hospitals or through medical registries and diagnosed using research-based assessments administered by clinicians or trained staff. 19,099 cases and 34,194 controls of European ancestry were included in the current study.

Autism spectrum disorder | Grove et al., 2017

Five family-based cohorts of European descent and a population-based case-control sample from Denmark were combined to discover five loci associated with autism spectrum disorder. In each family study, diagnosis was confirmed for all affected individuals using standard research tools and expert clinical consensus diagnosis. In the population-based cohort, cases were identified using the Danish Psychiatric Central Research Register and were diagnosed with ASD before 2013 by a psychiatrist according to ICD-10. All subjects in this sample were included here (18,381 cases; 27,969 controls).

Obsessive compulsive disorder | IOCDF-GC and OCGAS, 2018

Individuals of European descent from two cohorts were combined in this meta-analysis including 2,688 cases and 7,037 controls; no loci reached genome-wide significance. Case diagnoses were established using DSM-IV criteria and controls were unscreened. All cases and controls were included in the current analyses.

Anorexia nervosa | Duncan et al., 2017

3,495 cases from two consortia and 10,982 matched controls from the Psychiatric Genomics Consortium, all of European descent, were meta-analyzed to identify one locus associated with anorexia nervosa. Cases met criteria as defined by DSM-IV for lifetime diagnosis of anorexia nervosa (restricting or binge-purging subtype), bulimia nervosa, or anorexia nervosa – not otherwise specified, anorexia nervosa
subtype. All individuals included in the primary study were included in the current analyses.

**Tourette Syndrome | Yu et al., in press, American Journal of Psychiatry**

Three case-control cohorts and one family-based cohort from Europe and North America including 4,819 cases and 9,488 controls of European ancestry were meta-analyzed to identify one locus associated with Tourette Syndrome. All cases met DSM-IV-TR or DSM-5 criteria for Tourette syndrome, except for 12 cases who met DSM-5 criteria for chronic motor or vocal tic disorder. All cases were recruited by Tourette syndrome specialty clinics or by email/online recruitment combined with validated, web-based phenotypic assessments.

**Genotype quality control, imputation, and association analysis**

All primary studies used the standardized PGC ricopili pipeline for quality control, imputation and association testing. Briefly, for each dataset, poor quality SNPs and samples missing >5% SNPs were removed. Next, pre-phasing and imputation were implemented using IMPUTE2 (Howie et al., 2011) and the 1000 Genomes reference panel. High quality SNPs (INFO > 0.8) with low missingness (<1%) were retained. A subset of these markers (MAF > 0.05; pruned for linkage disequilibrium, r² > 0.02) were used to assess relatedness and population stratification. Only one of any pair of related individuals was retained. Each imputed dataset was tested for association with the disease outcome of interest using an additive logistic regression model in PLINK (Purcell et al., 2007) with age, sex, and 10 principal components included as covariates. Finally, a meta-analysis within each disease category was done using an inverse-weighted fixed effects model. After extracting SNPs commonly exist in all eight disorder studies, we removed 3,591 SNPs whose alleles were incompatible. For palindromic SNPs, we compared allele frequencies between eight studies to check strand ambiguity. 50 SNPs with frequency difference greater than 15% from the 1KG reference was excluded. As a result, 6,786,994 autosomal SNPs remained for further analysis.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Genome-wide SNP-heritability estimation**

For each of the eight GWAS disorders, LD Score regression was performed on the summary statistics of individual disease using LDSC to estimate SNP-based heritability in the liability scale and genetic correlation between pairs of disorders (Bulik-Sullivan et al., 2015b). LD scores and weights for European populations were downloaded from the LDSC website (http://www.broadinstitute.org/~bulik/eur_ldscores/). SNPs were removed if the minor allele frequency is smaller than 5% or an imputation quality score is less than 0.9; MHC region was excluded from the analysis. For single-trait LDSC, the slope of the regression estimates the SNP-based heritability, and the intercept captures the inflation in the summary statistics due to population stratification or other confounding
factors. We confirmed that the heritability Z-scores (i.e., a measure of the polygenic signals) are greater than four, and the LDSC intercepts are approximately one and less than $\lambda_C$. This suggests that the increase in mean $\chi^2$ statistics is mostly due to polygenicity and not due to stratification.

**Factor analysis and genomic SEM**

Genomic SEM's Multivariable LD score regression method (Grotzinger et al., 2018) was first used to estimate the genetic covariance matrix ($S$) and sampling covariance matrix ($V$) for the eight psychiatric traits. Quality control for this step included removing SNPs with an MAF < 1%, information scores < .9, SNPs from the MHC region, and filtering SNPs to HapMap3. All SNP effects were standardized using the sumstats function in Genomic SEM. To examine genome-wide factor structure, models using only the genetic covariance and sampling covariance matrix were fit. Genomic SEM provides indices of model fit—standardized root mean square residual (SRMR), model $\chi^2$, Akaike Information Criteria (AIC), and Comparative Fit Index (CFI)—that can be used to determine how well the proposed model captures the observed data. Model fit for the common factor model in which the loadings were freely estimated was only fair, ($\chi^2$ (20) = 313.94, AIC = 345.9, CFI = .786, SRMR = .149), suggesting that there were nuances in the genetic architecture not fully captured by a single cross-trait index of genetic risk. An exploratory factor analysis (EFA) of the S matrix with three-factors using the promax rotation in the R package factanal was then used to guide construction of a follow-up model (Supplementary Table 3). A follow-up confirmatory model with three correlated factors was specified in Genomic SEM based on the EFA parameter estimates (positive standardized loadings > .2 were retained; Figure 2b). This model provided good fit to the data ($\chi^2$ (15) = 85.35, AIC = 127.36, CFI = .945, SRMR = .079). Results indicated there was a moderate genetic correlation between the compulsive and mood/psychotic disorders factors ($r_g = .43, SE = .07$), a smaller genetic correlation between the mood/psychotic and early onset factors ($r_g = .24, SE = .05$), and next to no correlation between the compulsive and early onset factors ($r_g < .01, SE = .07$). A model that included additional negative cross-loadings provided similar fit to the data and highly similar correlations across the genetic factors. Given this consistency in results, the correlated factors model with SNP effects only included positive loadings.

**Summary-data-based meta-analysis**

To identify genomic loci shared across multiple neuropsychiatric disorders, we performed primary meta-analysis using the subset-based fixed-effects method ASSET (Bhattacharjee et al., 2012). Standard meta-analysis pools the effect of a given SNP across $K$ studies, weighting the effects by the size of the study. In this subset-based meta-analysis, this basic procedure – as well as a null probability distribution for a SNP having no effect in any study – was calculated for all subsets of studies to determine a given SNP’s subset-specific effect. The maximum SNP effect across subsets can be denoted
\( Z_{\text{max\text{-}meta}} = \max_{S \in \mathcal{S}} |Z(S)|, \)

where the absolute value of the subset-specific effect \(|Z(S)|\) over class \(S\) of all possible subsets of \(K\) studies is highest. The numbers of shared subjects across eight disorder studies were identified using the PGC checksum algorithm, and \(Z_{\text{meta}}\) was standardized so that covariance between the statistics can be accounted for as previously described (Bhattacharjee et al., 2012; Lin and Sullivan, 2009). Tail probabilities for the distribution of the maximum were then estimated with the discrete local maxima method, which uses the correlation structure of test statistics across subsets. Based on this distribution, a \(p\)-value was derived using a one-sided test of the test statistic \((Z)\); each directional test can then be combined using a chi-square method (Fisher’s combined \(p\)-value method). Even when correcting for all subset tests \((2^K-1)\), simulations suggest there is a substantial gain in power using this test relative to traditional meta-analysis.

Once SNPs with genome-wide significant association were identified, we identified LD-independent genomic regions using PLINK clumping (\(--\text{clump-r2}=0.4\), \(--\text{clump-kb}=500\), \(--\text{clump-p1}=5\times10^{-8}\), \(--\text{clump-p2}=5\times10^{-02}\) ). Genomic regions were merged if they physically overlap using bedtools. Due to extensive LD, the MHC region was considered as one region (chr6:25-35Mb). To detect secondary signals independent of index SNP in each of the candidate cross-disorder loci, conditional analysis was performed with GCTA-COJO (Yang et al., 2012) using meta-analysis summary statistics from ASSET. 1KG EUR population was used as the reference panel for estimating LD. For each genomic region harboring a cross-disorder signal, we tested the presence of any additional associated SNPs using a stepwise procedure (\(--\text{cojo-slc}\) ), conditioning on the primary significant SNP for model initiation. A conditional \(p\)-value for each variant was reported, adjusted for genomic control and collinearity. In each region, additional SNPs were selected as a distinct association signal if having a conditional \(p\)-value < 1e-06.

**Disease-association modeling**

We estimated posterior probabilities for each of the top loci identified from the meta-analysis to quantify disorder-specific effects (Han and Eskin, 2012). This estimation, known as the \(m\)-value, relies on two assumptions, 1) effects are either present or absent in studies, and 2) if they are present, they are similarly sized across studies. Assume \(X_i\) is the observed effect size of study \(i\), and \(T_i\) is a random variable with value 1 if study \(i\) has an effect and 0 if not, then the \(m\)-value can be estimated using Bayes’ theorem:

\[
m_i = P(T_i = 1 | X) = \frac{P(X|T_i = 1)P(T_i = 1)}{P(X|T_i = 1)P(T_i = 1) + P(X|T_i = 0)P(T_i = 0) + P(X|T_i = 1)P(T_i = 1)}
\]

which can then be used to predict whether an effect exists in a given study (> .9) or not (< .1) under the binary effects assumption. For further details, refer to the publication by Han & Eskin (2012).
Functional annotation and gene-mapping of genome-wide significant variants

For the 146 genome-wide significant variants, gene mapping and functional annotation was conducted using various resources, including SNP Nexus (Dayem et al., 2018) and FUMA (Watanabe et al., 2017). Nearest genes and functional consequence of each SNP on gene functions were annotated based on ANNOVAR (Wang et al., 2010). Combined Annotation Dependent Depletion (CADD) score (Kircher, 2014) indexes the deleteriousness of variants computed based on 67 annotation resources. SNPs with the CADD score higher than 12 were considered to confer deleterious effects. The RegulomeDB (Boyle, 2012) provides a categorical score that describes how likely a SNP is likely to play a regulatory role based on the integration of high-throughput datasets. The RDB score of 1a suggests the strongest evidence while the score 7 represents the least support for a regulatory potential. The minChrState and the commonChrState represent the minimum and the most common 15-core chromatin state across 127 tissue/cell type predicted by ChrHMM. The chromatin state of less than 8 suggests an open chromatin state. We also performed eQTL mapping, which provides significant cis-SNP-gene pairs (up to 1Mb apart) in brain tissue types from GTEx and BRAINEAC.

For chromatin interaction mapping, we first refined the localization of potential causal variants for top 146 lead SNPs. We then used FINEMAP (Benner et al., 2016) to identify credible SNPs. For each region, we considered only SNPs located in the LD region with the lead SNP ($r^2 > 0.6$). We then applied the method to calculate the posterior probability of being causal for each of the remaining SNPs. A 95% credible set of SNPs for each region was constructed by ordering the posterior probability from largest to smallest and selecting in the corresponding SNPs up to a cumulative probability of 95%. Credible SNPs were then grouped into those that are located within the promoter or exons and those that are non-coding/intronic. Promoter/exonal SNPs were directly assigned to their target genes using positional mapping, while non-coding/intronic SNPs were assigned to their target genes based on long range interactions (Hi-C) or expression quantitative trait loci (eQTLs). Two Hi-C datasets originated from the human brain (fetal brain Hi-C (Won et al., 2016) and adult brain Hi-C (Wang et al., 2018)) were used to map credible SNPs as previously described (Wang et al., 2018). A colocalization analysis with the recent eQTL dataset from adult prefrontal cortices (PFC) was also used to map 146 GWS loci into their target genes (Wang et al., 2018). In the end, we obtained two sets of candidate genes, one from fetal brain (positional mapping, fetal brain Hi-C), the other from adult brain (positional mapping, adult brain Hi-C, adult brain eQTLs).

GTEx gene expression enrichment analysis

MAGMA gene-property analysis (de Leeuw et al., 2015) was performed using gene expression data from 83 tissues based on GTEx RNA-seq data (v7). Expression values (RPKM) were log2 transformed with pseudo-count one after winsorization at 50, and
average expression values were taken per tissue. Analysis was performed separately for 30 general tissue types and 53 specific tissue types.

**Pathway analysis using Gene Ontology**

We used FUMA (Watanabe et al., 2017) to map SNPs to genes and then test for enrichment of specific Gene Ontology functions and pathways among genome-wide significant pleiotropic and disorder-specific SNPs separately. Hypergeometric tests identify any statistical over-representation of genes from the input list (mapped from SNPs) in predefined Gene Ontology gene sets which describe biological processes, molecular functions, and cellular components. Multiple test correction was applied by category.

**Enrichment analysis using brain developmental, regional, and cell-type-specific data**

Developmental expression trajectories for candidate genes were plotted using a published transcriptome atlas constructed from post-mortem brain data (Kang et al. 2011). Expression values were log-transformed and centered using the mean expression values for all brain expressed genes. Mean expression values for candidate genes were plotted across prenatal (6-37 weeks post-conception) and postnatal (4 months to 62 years) developmental stages. We used candidate genes identified in fetal brain and adult brain to plot prenatal and postnatal gene expression profiles, respectively.

To obtain genes that show cortical regional enrichment (e.g. frontal cortical enrichment), we computed t-statistics for each gene for a specific cortical region (e.g. frontal cortex) versus all other cortical regions (e.g. parietal cortex, temporal cortex, and occipital cortex, Kang et al. 2011). Top 5% of genes that show specific expression patterns for each cortical region were selected as region-specific genes. These genes were then overlapped with candidate genes by Fisher’s exact test to measure cortex regional enrichment.

Single cell expression profiles from the adult brain (Darmanis et al., 2015) were used to identify cell-type specificity of candidate genes. Single cell expression values were log-transformed and centered using the mean expression values. Average centered expression values for candidate genes were calculated in each cell. Cells were then grouped into cell clusters (neurons, astrocytes, microglia, oligodendrocytes, OPC, and endothelial cells), and a relative expression level for a given cell cluster was calculated by a *scale* function in R.

Developing neural cell-type enrichments were estimated using expression profiles of single-cells taken from fetal cortical laminae. Cell-type specific genes were selected according to a significant Pearson correlation (FDR < 0.05) between the gene and an
idealized cluster marker for each cell-type, following the approach described in original publication. Candidate gene enrichment for each set of specifically expressed genes was estimated by logistic regression and adjusting for gene length.

**Comparison with other brain-related traits and diseases**

To look for other traits that show an association with our top loci, we examined publicly available GWAS summary statistics of 11 brain-related and 10 non-brain-related traits and disorders. The selected brain-related traits include Alzheimer’s disease (Lambert et al., 2013), anxiety (Otowa et al., 2016), all epilepsies (International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address, 2014), genetic generalized epilepsy (International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address, 2014), non-acquired focal epilepsy (International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address, 2014), intracerebral hemorrhage (Woo et al., 2014), post-traumatic stress disorder (Duncan et al., 2018), ischemic stroke (all) (Malik et al., 2016), cardioembolic stroke (Malik et al., 2016), large-vessel disease (Malik et al., 2016), and small vessel disease (Malik et al., 2016), non-brain-related traits include height (Wood et al., 2014), obesity (Berndt et al., 2013), Crohn’s disease (Goyette et al., 2015; Liu et al., 2015), inflammatory bowel disease (Goyette et al., 2015; Liu et al., 2015), ulcerative colitis (Goyette et al., 2015; Liu et al., 2015), coronary artery disease (Nikpay et al., 2015), sleep duration (Jones et al., 2016), number of children ever born (Barban et al., 2016), subject well-being (Okbay et al., 2016), and neuroticism (Okbay et al., 2016). Data source and sample size information for each individual GWAS can be found in Table S16. All the summary results files were harmonized before use, with reference and effect alleles matched up across studies for each index SNP. We then extracted the association statistics of the lead SNPs—effect sizes with standard errors (or Z-scores) and p-values—with each of the traits listed herein. Where the index variant was not available, the nearest proxy SNP ($r^2 > 0.8$) was used for reporting the association.

**DATA AND SOFTWARE AVAILABILITY**

The Psychiatric Genetics Consortium (PGC)’s policy is to make genome-wide summary results publicly available. Summary statistics for a combined meta-analysis of eight psychiatric disorders without 23andMe data are available on the PGC web site (https://www.med.unc.edu/pgc/results-and-downloads). Results for 10,000 SNPs for eight disorders including 23andMe are also available on the PGC web site. The summary-level GWAS association statistics for PGC individual disorders are available at the website (https://www.med.unc.edu/pgc/results-and-downloads).

GWAS summary statistics for the 23andMe cohort (Hyde, 2016) must be obtained separately. These can be obtained by individual researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Contact Aaron Petrikovitz (apetrakovitz@23andme.com) to apply for access to the data.
Supplementary Tables

Table S1. Summary of eight neuropsychiatric disorder datasets (Related to Table 1). Disease-specific cases and controls included in the meta-analysis, number of individual GWAS loci, and liability-based SNP heritability estimates are provided. Heritability was estimated from available European summary statistics using LD score regression.

Table S2. Genetic correlations estimated by LD score regression. (Related to Figure 1) Genetic correlations and standard errors between pairs of disorders were estimated from European GWAS summary statistics using LD score regression.

Table S3. Results from EFA of genetic covariance matrix (Related to Figure 1 and Figure S1) We estimated the genetic covariance matrix across eight psychiatric traits using genomic SEM and then performed an exploratory factor analysis, which revealed three factors. Individual disease loadings on each factor are listed as well as correlations between factors.

Table S4. List of 146 lead SNPs (Related to Figure 3 and Figure S2) The cross-disorder fixed-effects meta-analysis identified 136 loci and within these loci, multi-SNP-based conditional analyses identified 10 additional SNPs. The details of these 146 lead SNPs, as well as the posterior probability of disease-specific associations estimated using a Bayesian statistical framework are listed.

Table S5. Disorder-specific association (Related to Figure 3 and Figure S2) Disease-specific associations are listed for all 146 lead SNPs.

Table S6. Loci with opposite directional effects (Related to Figure 4) SNPs with a cross-disorder meta-analysis $p \leq 1 \times 10^{-6}$ that showed disorder-specific effects in opposite directions are listed along with the effects for each disease.

Table S7. Functional annotation of 146 lead SNPs (Related to Table S4) Functional annotation for the genome-wide significant SNPs was done using SNP Nexus, FUMA, and ANNOVAR. SNPs were mapped to the nearest gene within 100kb when possible and various functional consequences were annotated including combined annotation dependent depletion (CADD) scores, which reflect the deleteriousness of variants based on 67 annotation resources, and likelihood SNP plays a regulatory role based on the RegulomeDB (1 = strongest; 7 = weakest).
Table S8. Brain eQTL and Hi-C data annotation based on FUMA database (Related to Table S4)
Genome-wide significant SNPs were tested for any eQTL effects in brain tissues. Significant cis-SNP-gene pairs (up to 1Mb apart) identified in GTEx (v7) or BRAINEAC are listed along with associated p-values. Additionally, fine-mapping for the 146 lead SNPs was done using an efficient summary statistics-based Bayesian method to identify a 99% credible set of SNPs for each region. These SNPs were used to identify long-range interactions with the regions harboring a candidate SNP using brain Hi-C datasets. The Hi-C tissue, regions, and p-values were reported.

Table S9. GWAS catalog data for lead SNPs (Related to Table S4)
The NHGRI-EBI GWAS Catalog was queried for each SNP to identify all traits previously associated with a lead SNP (p-value < 1x10^-5), along with the corresponding effect sizes and p-values.

Table S10. GTEx gene enrichment analysis using MAGMA (Related to Figure 5)
To investigate enrichment of lead SNPs within certain tissue types, we performed a MAGMA gene-property analysis using gene expression data from 83 tissues based on GTEx RNA-seq data (v7). Enrichment statistics for each tissue are listed.

Table S11. Tissue enrichment analysis for pleiotropic risk loci using MAGMA (GTEx v7) (Related to Figure 5)
To evaluate pleiotropic-specific effects, we assessed enrichment for the 109 pleiotropic lead SNPs using MAGMA and 83 tissues based on GTEx v7. The statistics for each tissue are listed.

Table S12. Tissue enrichment analysis for disorder-specific risk loci using MAGMA (GTEx v7) (Related to Figure 5)
To evaluate disorder-specific effects, we assessed enrichment for non-pleiotropic lead SNPs using MAGMA and 83 tissues based on GTEx v7. The statistics for each tissue are listed.

Table S13. Gene ontology analysis for pleiotropic loci (Related to Result - Functional characterization of pleiotropic risk loci)
We used Gene Ontology data to identify any enrichment among the 109 pleiotropic SNPs for specific biological processes (GO_bp), molecular functions (GO_mf), or cellular components (GO_cc). Gene sets for which significant enrichment was identified are listed along with raw and adjusted p-values.

Table S14. GO enrichment analysis for disease-specific risk loci (Related to Result - Functional characterization of pleiotropic risk loci)
We used Gene Ontology data to identify any enrichment among the 37 disease-specific loci for specific biological processes (GO_bp), molecular functions (GO_mf), or cellular components (GO_cc). Gene sets for which significant enrichment was identified are listed along with raw and adjusted p-values.

**Table S15. GWAS Catalog enrichment analysis for top genome-wide significant loci (Related to Result - Functional characterization of pleiotropic risk loci)**

For traits in the NHGRI-EBI GWAS Catalog, we mapped genome-wide significant loci to genes and then assessed the overlap between genes for a given trait and genes linked to the top loci for the current meta-analysis. We calculated p-values associated with the degree of overlap relative to what would have been expected by chance.

**Table S16. Comparison of disease-specific vs. pleiotropic risk loci by various functional and genomic features (Related to Result - Functional characterization of pleiotropic risk loci)**

Functional and genomic features were compared between pleiotropic and non-pleiotropic loci. Statistics from t-tests, as well as ANOVAs, comparing these two groups were reported.

**Table S17. Genetic correlation analysis of top cross-disorder loci with 28 brain-related traits (Related to Result - Relationship between cross-disorder genetic risk and other brain-related traits and diseases)**

We used LD score regression to estimate genetic correlations between cross-disorder risk and 28 other publicly available brain-related traits. These effects, along with data source and sample size information for each individual GWAS were listed.

**Table S18. GWAS catalog enrichment analysis for pleiotropic risk loci (Related to Result - Relationship between cross-disorder genetic risk and other brain-related traits and diseases)**

We used Gene Ontology data to identify any enrichment among the 109 pleiotropic SNPs for brain-related traits. Gene sets for which significant enrichment was identified are listed along with raw and adjusted p-values.
Figure S1. Hierarchical clustering of genetic architecture across eight neuropsychiatric disorders. (Related to Table S3) Hierarchical clustering revealed three sub-groups within the eight disorders. Results were very similar to those obtained using exploratory factor analysis and genomic structural equation modeling.
Cluster Dendrogram

hclust (*, "single")

TC
AN
OCD

ADHD
MDD
ASD

SCZ
BIP
Figure S2. P-M plots for top 146 loci. (Related to Figure 3 and Table S5) M-values were generated for each locus for each disorder and indicate the presence or absence of a disorder-specific effect. M-values were plotted with the negative log odds of the corresponding p-values for each disorder for a given SNP; P-M plots were generated for each of the top 146 loci. Log odds ratios for the effect of the SNP on each disorder and a summary across disorders was also plotted. As expected, most of the top SNPs (109/146) were pleiotropic.
rs4702 (Meta \( P = 2.46 \times 10^{-11} \))

**Gene**: FURIN, FES

**GWAS P-value**
- \(2.55 \times 10^{-12}\)
- 0.0007
- 0.0004
- 0.1043
- 0.0023
- 0.9832
- 0.4189
- 0.9787

**FE summary**

**PM-Plot**
rs12552 (Meta $P = 1.25 \times 10^{-18}$)

Gene: **OLFM4**

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.6012</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0191</td>
<td>2.BIP</td>
</tr>
<tr>
<td>4.00 x 10^{-19}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0215</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0214</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1894</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.7859</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.6274</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

- log10(p)

m-value
rs27419 (Meta $P = 1.11 \times 10^{-8}$)

Gene: **MOCS2, ITGA2**

GWAS P-value

<table>
<thead>
<tr>
<th>p-value</th>
<th>SCZ</th>
<th>BIP</th>
<th>MD</th>
<th>ASD</th>
<th>ADHD</th>
<th>TS</th>
<th>ANO</th>
<th>OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.78 x $10^{-6}$</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>0.4544</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0308</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.15 x $10^{-5}$</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0486</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0236</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.9813</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2481</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FE summary

PM-Plot

---

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs174592 (Meta \( P = 6.14 \times 10^{-9} \))

Gene: \textit{FADS2}, \textit{FADS3}

GWAS P-value

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1767</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>(4.03 \times 10^{-8})</td>
<td>2.BIP</td>
</tr>
<tr>
<td>(5.15 \times 10^{-7})</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.6023</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.6852</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.4253</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.3221</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4378</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

- log_{10}(p)

FE summary

Log odds ratio

PM-Plot

\( m \)-value
rs247910 (Meta $P = 2.69 \times 10^{-9}$)

Gene: TMEM161B

GWAS P-value

- 0.9569 for 1.SCZ
- 0.6117 for 2.BIP
- $1.28 \times 10^{-10}$ for 3.MD
- 0.0013 for 4.ASD
- $6.34 \times 10^{-6}$ for 5.ASD
- 0.1899 for 6.TS
- 0.1783 for 7.ANO
- 0.1837 for 8.OCD

FE summary

Log odds ratio

PM-Plot

m-value

- log10(p)
rs301799 (Meta $P = 1.69 \times 10^{-8}$)

Gene: RERE, SLC45A1

GWAS $P$-value

- 6.91 x $10^{-7}$ (1.SCZ)
- 0.5613 (2.BIP)
- 3.38 x $10^{-8}$ (3.MD)
- 0.1411 (4.ASD)
- 0.1888 (5.ASD)
- 0.0016 (6.TS)
- 0.1181 (7.ANO)
- 0.0233 (8.OCD)

FE summary

Log odds ratio

GWAS $P$-value summary

- 6.91 x $10^{-7}$
- 0.5613
- 3.38 x $10^{-8}$
- 0.1411
- 0.1888
- 0.0016
- 0.1181
- 0.0233

PM-Plot

- m-value
- $-\log_{10}(p)$

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.
http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs395138 (Meta $P = 1.03 \times 10^{-8}$)

Gene: ENOX1

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0005</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.1196</td>
<td>2.BIP</td>
</tr>
<tr>
<td>4.70 x $10^{-8}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.9349</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0946</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.2091</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.2456</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.2081</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

PM-Plot

- log10(p)

m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs631399 (Meta $P = 6.6e \times 10^{-11}$)

Gene: (>200kb)

GWAS $P$-value
- 0.3915, SCZ
- 0.7224, BIP
- $5.21 \times 10^{-12}$, MD
- 0.4672, ASD
- 0.0656, ADHD
- 0.2382, TS
- 0.1053, ANO
- 0.1307, OCD

FE summary

Log odds ratio

GWAS $P$-value

- 0.3915
- 0.7224
- $5.21 \times 10^{-12}$
- 0.4672
- 0.0656
- 0.2382
- 0.1053
- 0.1307

PM-Plot

$-\log_{10}(p)$

0.0 0.2 0.4 0.6 0.8 1.0

0 5 10 15 20

0.0 0.2 0.4 0.6 0.8 1.0
rs732381 (Meta $P = 6.87 \times 10^{-11}$)

Gene: **CACNA1I, ENTHD1**

GWAS $P$-value

- 2.11 x $10^{-10}$
- 1.87 x $10^{-5}$
- 0.0026
- 0.7357
- 0.9892
- 0.3788
- 0.6395
- 0.1040

Log odds ratio

- 0.15
- 0.10
- 0.05
- 0.00
- 0.05
- 0.10

FE summary

PM–Plot

GWAS $P$-value

- 2.11 x $10^{-10}$
- 1.87 x $10^{-5}$
- 0.0026
- 0.7357
- 0.9892
- 0.3788
- 0.6395
- 0.1040

- log$_{10}$($p$)

- m-value
rs746839 (Meta $P = 2.94 \times 10^{-8}$)

Gene: MROH5

GWAS P-value

- $3.46 \times 10^{-5}$ for 1.SCZ
- 0.9886 for 2.BIP
- 0.0843 for 3.MD
- $4.36 \times 10^{-6}$ for 4.ASD
- 0.9340 for 5.AHD
- 0.2594 for 6.TS
- 0.0818 for 7.ANO
- 0.3752 for 8.OCD

FE summary

Log odds ratio

PM-Plot

$-\log_{10}(p)$

m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.

do:bioRxiv preprint first posted online Jan. 26, 2019;
rs760648 (Meta $P = 1.08 \times 10^{-8}$)

**Gene:** TCF20, CYP2D6

### GWAS P-value

- $1.32 \times 10^{-10}$: SCZ
- 0.0058: BIP
- 0.0020: MD
- 0.0418: ASD
- 0.4099: ADHD
- 0.3636: TS
- 0.1483: ANO
- 0.5519: OCD

### Log odds ratio

- $-0.10$ to $0.10$

### PM-Plot

- m-value
- $-\log_{10}(p)$

---

This image is licensed under a [CC-BY-NC-ND 4.0 International license](http://dx.doi.org/10.1101/528117).
rs778353 (Meta $P = 2.06 \times 10^{-11}$)

**Gene:** NGEF, C2orf82

GWAS $P$-value

- $1.60 \times 10^0$: 1.SCZ
- $1.69 \times 10^{-5}$: 2.BIP
- $0.2353$: 3.MD
- $0.1101$: 4.ASD
- $0.2931$: 5.AHD
- $0.0025$: 6.TS
- $0.0124$: 7.ANO
- $0.9953$: 8.OCD

FE summary

Log odds ratio

GWAS $P$-value

- 1.60 $\times 10^0$
- 1.69 $\times 10^{-5}$
- 0.2353
- 0.1101
- 0.2931
- 0.0025
- 0.0124
- 0.9953

**PM-Plot**

$-\log_{10}(p)$ vs $m$-value

1. SCZ
2. BIP
3. MD
4. ASD
5. ADHD
6. TS
7. ANO
8. OCD
rs832190 (Meta $P = 3.6 \times 10^{-9}$)

Gene: THOC7, ATXN7

GWAS P-value

- $6.18 \times 10^{-10}$, red circle, 1.SCZ
- 0.0055, green circle, 2.BIP
- 0.4596, blue circle, 3.MD
- 0.0696, green circle, 4.ASD
- 0.3673, green circle, 5.ASD
- 0.9885, green circle, 6.TS
- 0.2214, blue circle, 7.ANO
- 0.0110, green circle, 8.OCD

FE summary

Log odds ratio

PM–Plot

- $- \log_{10}(p)$
rs880090 (Meta $P = 1.15 \times 10^{-9}$)

Gene: GMIP, LPAR2

GWAS P-value
- $9.90 \times 10^{-7}$ (1.SCZ)
- $2.05 \times 10^{-6}$ (2.BIP)
- 0.3177 (3.MD)
- 0.0078 (4.ASD)
- 0.4825 (5.AHD)
- 0.2028 (6.TS)
- 0.2688 (7.ANO)
- 0.1456 (8.OCD)

Log odds ratio
- $-0.15$
- $-0.10$
- $-0.05$
- $0.00$
- $0.05$
- $0.10$

FE summary

PM-Plot

- $0.0$
- $0.2$
- $0.4$
- $0.6$
- $0.8$
- $1.0$

$-\log_{10}(p)$
- $5$
- $10$
- $15$
- $20$

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. http://dx.doi.org/10.1101/528117 doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs915057 (Meta $P = 2.76 \times 10^{-9}$)

**Gene:** SYNE2, ESR2

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>SCZ</th>
<th>BIP</th>
<th>MD</th>
<th>ASD</th>
<th>ADHD</th>
<th>TS</th>
<th>ANO</th>
<th>OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2128</td>
<td>0.9648</td>
<td>9.26 x $10^{-10}$</td>
<td>0.0674</td>
<td>0.1099</td>
<td>0.2040</td>
<td>0.0173</td>
<td>0.8569</td>
<td></td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

- $\log_{10}(p)$ vs. $m$-value
Gene: **GRIK3**

GWAS P-value

- 0.0057 1.SCZ
- 0.0139 2.BIP
- 5.83 x 10^{-8} 3.MD
- 0.1378 4.ASD
- 0.6600 5.AHDR
- 0.3156 6.TS
- 0.6629 7.ANO
- 0.1869 8.OCD

Log odds ratio

FE summary

**PM-Plot**

GWAS P-value

- 0.0057 1.SCZ
- 0.0139 2.BIP
- 5.83 x 10^{-8} 3.MD
- 0.1378 4.ASD
- 0.6600 5.AHDR
- 0.3156 6.TS
- 0.6629 7.ANO
- 0.1869 8.OCD

FE summary

**PM-Plot**

GWAS P-value

- 0.0057 1.SCZ
- 0.0139 2.BIP
- 5.83 x 10^{-8} 3.MD
- 0.1378 4.ASD
- 0.6600 5.AHDR
- 0.3156 6.TS
- 0.6629 7.ANO
- 0.1869 8.OCD

FE summary

**PM-Plot**
rs1226412 (Meta $P = 2.07 \times 10^{-8}$)

**Gene:** NR4A2

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.AHD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2232</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1415</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$1.82 \times 10^{-8}$</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.4833</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2740</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0126</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1174</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>0.0434</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

**FE summary**

**PM-Plot**

Log odds ratio

-0.05 0.00 0.05 0.10 0.15

- \log_{10}(p)

0 5 10 15 20

m-value

0.0 0.2 0.4 0.6 0.8 1.0

0 5 10 15 20

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs1484144 (Meta $P = 4.24 \times 10^{-9}$)

**Gene:** *NAA11*

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.ASD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0002</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>0.0073</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$3.06 \times 10^{-6}$</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0141</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$2.05 \times 10^{-6}$</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.6078</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.3156</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7845</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FE summary**

**PM-Plot**
rs1501361 (Meta $P = 3.97 \times 10^{-8}$)

**Gene**: $HCN1$

**GWAS P-value**

- $1.15 \times 10^{-6}$: 1.SCZ
- 0.0001: 2.BIP
- 0.7425: 3.MD
- 0.9779: 4.ASD
- 0.5544: 5.ADH
- 0.0026: 6.TS
- 0.7634: 7.ANO
- 0.6619: 8.OCD

**FE summary**

**Log odds ratio**

-1.00 -0.60 -0.20 0.00 0.20 0.40 0.60

**m-value**

0.0 0.2 0.4 0.6 0.8 1.0

---

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

rs1518367 (Meta $P = 1.06 \times 10^{-11}$)

**Gene:** PLCL1

**GWAS P-value**

- $2.82 \times 10^{-8}$ (1.SCZ)
- 0.0008 (2.BIP)
- $2.50 \times 10^{-7}$ (3.MD)
- 0.0790 (4.ASD)
- 0.0106 (5.ASD)
- 0.2833 (6.TS)
- 0.8309 (7.ANO)
- 0.3786 (8.OCD)

**PM-Plot**
rs1615350 (Meta P = 5.06 x 10^{-10})

Gene: MPHOSPH9, PITPNM2

GWAS P-value

- 4.55 x 10^{-12} for 1.SCZ
- 0.0539 for 2.BIP
- 0.3255 for 3.MD
- 0.7324 for 4.ASD
- 0.0351 for 5.ASHD
- 0.0003 for 6.TS
- 0.3616 for 7.ANO
- 0.6142 for 8.OCD

FE summary

Log odds ratio

GWAS P-value

- 4.55 x 10^{-12} for 1.SCZ
- 0.0539 for 2.BIP
- 0.3255 for 3.MD
- 0.7324 for 4.ASD
- 0.0351 for 5.ASHD
- 0.0003 for 6.TS
- 0.3616 for 7.ANO
- 0.6142 for 8.OCD

PM-Plot

m-value

- log_{10}(p)

PM-Plot

m-value

- log_{10}(p)
rs1702294 (Meta $P = 3.03 \times 10^{-16}$)

Gene: (>200kb)

GWAS P-value

- $9.50 \times 10^{-18}$  red circle 1.SCZ
- 0.3625 blue circle 2.BIP
- 0.9485 blue circle 3.MD
- 0.0364 blue circle 4.ASD
- 0.1618 blue circle 5.ADHD
- 0.7775 blue circle 6.TS
- 0.4654 blue circle 7.ANO
- 0.0440 green circle 8.OCD

FE summary

Log odds ratio

-0.20 -0.15 -0.10 -0.05 0.00 0.05 0.10

- $\log_{10}(p)$

-0.0 0.2 0.4 0.6 0.8 1.0

0 5 10 15 20

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs1730054 (Meta $P = 5.81 \times 10^{-10}$)

Gene: RSRC1

GWAS P-value

- 0.8542, 1.SCZ
- 0.0288, 2.BIP
- $2.56 \times 10^{-8}$, 3.MD
- 0.0001, 4.ASD
- 0.0050, 5.ASD
- 0.4081, 6.TS
- 0.1661, 7.ANO
- 0.0132, 8.OCD

FE summary

Log odds ratio

PM-Plot

- $-\log_{10}(p)$ vs. m-value

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs1806153 (Meta $P = 1.1 \times 10^{-9}$)

Gene: $PAX6, ELP4$

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2701</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.9572</td>
<td>2.BIP</td>
</tr>
<tr>
<td>9.43 x $10^{-10}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0006</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.2791</td>
<td>5.ADHD</td>
</tr>
<tr>
<td>0.3045</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4847</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.2514</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

-0.15 -0.10 -0.05 0.00 0.05 0.10

-\log_{10}(p)

0 5 10 15 20

m-value

0.0 0.2 0.4 0.6 0.8 1.0

PM-Plot

CC-BY-NC-ND 4.0 International license

It is made available under a [which was not peer-reviewed](https://doi.org/10.1101/528117) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.
rs1950829 (Meta $P = 2.27 \times 10^{-8}$)

**Gene**: LRFN5

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3738</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.7806</td>
<td>2.BIP</td>
</tr>
<tr>
<td>2.89 x $10^{-9}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.2053</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3316</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.2093</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.0494</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3395</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**FE summary**

**PM-Plot**
rs2003490 (Meta $P = 1.56 \times 10^{-8}$)

**Gene:** RPS6KL1, DLST

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.ASDH</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0033</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.4137</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$8.67 \times 10^{-9}$</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.8929</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2640</td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0661</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.9596</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.4357</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td></td>
</tr>
</tbody>
</table>

FE summary

![Log odds ratio vs. m-value plot with significant GWAS P-values marked for each disorder.](attachment:image.png)
rs2047568 (Meta $P = 4.3 \times 10^{-8}$)

Gene: **SPPL3, ACADS**

GWAS $P$-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0004</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0044</td>
<td>2.BIP</td>
</tr>
<tr>
<td>$9.77 \times 10^{-7}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.3844</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.4364</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.3731</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4305</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.6930</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

$-0.08 \quad -0.04 \quad 0.00 \quad 0.02 \quad 0.04 \quad 0.06 \quad 0.08$

$-\log_{10}(p)$

$0 \quad 5 \quad 10 \quad 15 \quad 20$

m-value

$0.0 \quad 0.2 \quad 0.4 \quad 0.6 \quad 0.8 \quad 1.0$

PM-Plot
rs2057884 (Meta $P = 3.68 \times 10^{-10}$)

Gene: **SRPK2**

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>SCZ</th>
<th>BIP</th>
<th>MD</th>
<th>ASD</th>
<th>ADHD</th>
<th>TS</th>
<th>ANO</th>
<th>OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.86 x $10^{-9}$</td>
<td>○</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0674</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0138</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0005</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0025</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2443</td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7256</td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7156</td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

GWAS P-value

- log10($p$)

PM-Plot

m-value

CC-BY-NC-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. http://dx.doi.org/10.1101/528117 doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs2098651 (Meta $P = 7.06 \times 10^{-9}$)

Gene: TENM2

GWAS P-value:
- 0.2245 for SCZ
- 0.0931 for BIP
- 9.75 x $10^{-9}$ for MD
- 0.0164 for ASD
- 0.0025 for ADHD
- 0.1457 for TS
- 0.4392 for ANO
- 0.1313 for OCD

PM-Plot

FE summary

Log odds ratio

-0.10
-0.05
0.00
0.05
0.10

m-value

0.0
0.2
0.4
0.6
0.8
1.0

- $\log_{10}(p)$
rs2103655 (Meta $P = 1.07 \times 10^{-9}$)

**Gene:** $PPP1R16B, ACTR5$

**GWAS P-value**

- $1.21 \times 10^{-10}$ (red circle) for 1.SCZ
- 0.0806 (blue triangle) for 2.BIP
- 0.1127 (black square) for 3.MD
- 0.9475 (blue triangle) for 4.ASD
- 0.2736 (black square) for 5.ASDD
- 0.6443 (blue triangle) for 6.TS
- 0.8812 (blue triangle) for 7.ANO
- 0.0189 (green circle) for 8.OCD

**FE summary**

- Log odds ratio
- $m$-value
- $-\log_{10}(p)$
rs2300861 (Meta \( P = 8.39 \times 10^{-9} \))

Gene: **AKAP6**

<table>
<thead>
<tr>
<th>GWAS P–value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1.14 \times 10^{-5})</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0779</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.4911</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.3421</td>
<td>4.ASD</td>
</tr>
<tr>
<td>(9.65 \times 10^{-6})</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0060</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.0547</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4607</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**PM–Plot**

Log odds ratio

\[-0.15\] \(-0.10\) \(-0.05\) \(0.00\) \(0.05\) \(0.10\)

\[-\log_{10}(p)\]

\[0\] \(5\) \(10\) \(15\) \(20\)

\[0.0\] \(0.2\) \(0.4\) \(0.6\) \(0.8\) \(1.0\)

FE summary
rs2332700 (Meta $P = 4.5 \times 10^{-10}$)

Gene: *RGS6*

GWAS P-value
- $6.91 \times 10^{-10}$, 1.SCZ
- 0.0360, 2.BIP
- $7.37 \times 10^{-6}$, 3.MD
- 0.0329, 4.ASD
- 0.9031, 5.AHD
- 0.6487, 6.TS
- 0.1897, 7.ANO
- 0.1956, 8.OCD

FE summary

PM–Plot
rs2388334 (Meta $P = 1.48 \times 10^{-11}$)

Gene: (>200kb)

GWAS $P$-value

- 0.0025, 1.SCZ
- $8.27 \times 10^{-8}$, 2.BIP
- 0.3378, 3.MD
- $9.30 \times 10^{-7}$, 4.ASD
- 0.6250, 5.ADH
- $9.51 \times 10^{-5}$, 6.TS
- 0.0553, 7.ANO
- 0.2511, 8.OCD

FE summary

Log odds ratio

Log odds ratio range:
- $-0.15$ to $0.15$

GWAS $P$-value range:
- $0.0025$ to $0.2511$

PM-Plot

$- \log_{10}(p)$

$m$-value

$0.0$ to $1.0$

$0$ to $20$
rs2391734 (Meta $P = 1.5 \times 10^{-8}$)

Gene: (>200kb)

GWAS $P$-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.6114</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.3238</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0885</td>
<td>3.MD</td>
</tr>
<tr>
<td>$3.87 \times 10^{-7}$</td>
<td>4.ASD</td>
</tr>
<tr>
<td>$6.80 \times 10^{-8}$</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0641</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.7727</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7565</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

$- \log_{10}(p)$
rs2391769 (Meta $P = 8.23 \times 10^{-9}$)

Gene: (>$200$kb)

GWAS $P$-value

- 0.4464 (1.SCZ)
- 0.2938 (2.BIP)
- 0.8572 (3.MD)
- $1.13 \times 10^{-7}$ (4.ASD)
- $9.50 \times 10^{-8}$ (5.ASHD)
- 0.8253 (6.TS)
- 0.4295 (7.ANO)
- 0.6369 (8.OCD)

FE summary

Log odds ratio

PM-Plot

$-\log_{10}(p)$ vs $m$-value

CC-BY-NC-ND 4.0 International license

It is made available under a

which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs2414718 (Meta $P = 1.36 \times 10^{-8}$)

**Gene:** (>200kb)

**GWAS P-value**
- $2.22 \times 10^{-10}$  1.SCZ
- 0.0087  2.BIP
- 0.5821  3.MD
- 0.8412  4.ASD
- 0.0065  5.ADH
- 0.1321  6.TS
- 0.7076  7.ANO
- 0.1895  8.OCD

**PM-Plot**
rs2514218 (Meta $P = 1.58 \times 10^{-11}$)

Gene: **DRD2**

GWAS P-value

- 4.82 x $10^{-10}$
- 0.0006
- 3.77 x $10^{-7}$
- 0.6562
- 0.1772
- 0.4333
- 0.1535
- 0.2341

FE summary

Log odds ratio

GWAS P-value plot

PM–Plot

- m-value
- $-\log_{10}(p)$
rs2522831 (Meta \( P = 2.01 \times 10^{-8} \))

**Gene:** PCLO

**GWAS P-value**
- 1.77 \( \times 10^{-6} \) (1.SCZ)
- 0.0035 (2.BIP)
- 1.33 \( \times 10^{-5} \) (3.MD)
- 0.1316 (4.ASD)
- 0.0078 (5.ASD)
- 0.8829 (6.TS)
- 0.0290 (7.ANO)
- 0.9455 (8.OCD)

**FE summary**

**PM–Plot**
rs2693698 (Meta $P = 3.04 \times 10^{-10}$)

Gene: BCL11B

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.71 x $10^{-8}$</td>
<td>SCZ</td>
</tr>
<tr>
<td>1.65 x $10^{-5}$</td>
<td>BIP</td>
</tr>
<tr>
<td>0.0104</td>
<td>MD</td>
</tr>
<tr>
<td>0.0279</td>
<td>ASD</td>
</tr>
<tr>
<td>0.0606</td>
<td>ADHD</td>
</tr>
<tr>
<td>0.0252</td>
<td>TS</td>
</tr>
<tr>
<td>0.0299</td>
<td>ANO</td>
</tr>
<tr>
<td>0.7599</td>
<td>OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

- $\log_{10}(p)$
- m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
Gene: *PDE4B*

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.59 x 10^{-8}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.7586</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.8224</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.2025</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0004</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.5265</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.1243</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.0984</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

−log_{10}(p)
rs2842198 (Meta $P = 9.7 \times 10^{-9}$)

Gene: HYI, SZT2

GWAS P-value

- $8.86 \times 10^{-5}$
- $0.2154$
- $0.8224$
- $0.5449$
- $6.40 \times 10^{-9}$
- $0.6534$
- $0.1259$
- $0.6439$

- 1.SCZ
- 2.BIP
- 3.MD
- 4.ASD
- 5.ASHD
- 6.TS
- 7.ANO
- 8.OCD

FE summary

Log odds ratio

PM–Plot
rs2910032 (Meta $P = 4.38 \times 10^{-8}$)

**Gene:** $(>200\,kb)$

**GWAS P-value**
- $5.42 \times 10^{-9}$  
- 0.0033  
- 0.0217  
- 0.1316  
- 0.0633  
- 0.7381  
- 0.0033  
- 0.6614  
- 0.0217  
- 0.1316  
- 0.7062  
- 0.0633  
- 0.7381  
- $0.0033$  
- 0.6614  
- 0.0217  
- 0.1316  
- 0.7062  
- 0.0633  
- 0.7381  
- $0.0033$  
- 0.6614  
- 0.0217  
- 0.1316  
- 0.7062  
- 0.0633  
- 0.7381  

**FE summary**

**PM-Plot**
rs3001723 (Meta $P = 7.44 \times 10^{-14}$)

**Gene:** *PTPRF, KDM4A*

### GWAS P-value
- 1.07 x $10^{-8}$, 1.SCZ
- 0.0179, 2.BIP
- 0.0647, 3.MD
- 0.2985, 4.ASD
- 4.99 x $10^{-10}$, 5.ASD
- 0.3560, 6.TS
- 0.8160, 7.ANO
- 0.4442, 8.OCD

### FE summary

---

### PM–Plot

---

*This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.*

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs3798869 (Meta $P = 7.69 \times 10^{-11}$)

**Gene**: SNAP91, PRSS35

**GWAS P-value**
- $1.25 \times 10^{-9}$ (Red) 1.SCZ
- $1.04 \times 10^{-5}$ (Red) 2.BIP
- 0.0196 (Blue) 3.MD
- 0.4202 (Blue) 4.ASD
- 0.8587 (Blue) 5.AHD
- 0.2079 (Green) 6.TS
- 0.6280 (Green) 7.ANO
- 0.0335 (Green) 8.OCD

**FE summary**

**PM–Plot**

GWAS $P$-value
- $1.25 \times 10^{-9}$
- $1.04 \times 10^{-5}$
- 0.0196
- 0.4202
- 0.8587
- 0.2079
- 0.6280
- 0.0335

**Log odds ratio**
- $-0.15$ to $0.05$

**m-value**
- 0.0 to 1.0
rs3812984 (Meta $P = 2.96 \times 10^{-9}$)

Gene: **PMFBP1, DHX38**

GWAS P-value
- 0.9268
- 0.0034
- $6.07 \times 10^{-8}$
- 0.0003
- 0.4321
- 0.6710
- 0.1377
- 0.1194

FE summary

PM-Plot
rs4129585 (Meta $P = 2.47 \times 10^{-15}$)

Gene: TSNARE1

GWAS P-value

- $3.45 \times 10^{-13}$: 1.SCZ
- 0.0061: 2.BIP
- 0.0055: 3.MD
- 0.5894: 4.ASD
- 0.3281: 5.ASD
- 0.2877: 6.TS
- 0.0003: 7.ANO
- 0.0005: 8.OCD

FE summary

PM-Plot
rs4242470 (Meta $P = 2.65 \times 10^{-8}$)

Gene: \textit{PXDNL, PCMTD1}

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0061</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0214</td>
<td>2.BIP</td>
</tr>
<tr>
<td>1.34 x $10^{-7}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.4732</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0840</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1541</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.3503</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4505</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

Log odds ratio

FE summary

PM–Plot

GWAS P-value

$-\log_{10}(p)$

m-value
rs4244354 (Meta $P = 2.27 \times 10^{-9}$)

**Gene**: ARL3, TRIM8

### GWAS P-value

- $1.74 \times 10^{-9}$, 1.SCZ
- $4.75 \times 10^{-5}$, 2.BIP
- 0.0061, 3.MD
- 0.1385, 4.ASD
- 0.6156, 5.AHD
- 0.6056, 6.TS
- 0.4566, 7.ANO
- 0.8858, 8.OCD

### Log odds ratio

<table>
<thead>
<tr>
<th>Log odds ratio</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.AHD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>−0.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>−0.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>−0.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>−0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PM-Plot

- m-value
- $-\log_{10}(p)$
rs4298967 (Meta $P = 7.91 \times 10^{-20}$)

**Gene: CACNA1C**

**GWAS P-value**
- $5.62 \times 10^{-8}$ 1.SCZ
- $3.46 \times 10^{-9}$ 2.BIP
- 0.0030 3.MD
- 0.1400 4.ASD
- 0.6098 5.ADH
- 0.1144 6.TS
- 0.3812 7.ANO
- 0.2051 8.OCD

**FE summary**

**PM-Plot**

GWAS P-value

0.0 0.2 0.4 0.6 0.8 1.0

- $-\log_{10}(p)$
rs4380187 (Meta $P = 8.48 \times 10^{-12}$)

Gene: ZNF804A

GWAS P-value

- $2.26 \times 10^{-11}$: 1.SCZ
- $1.15 \times 10^{-5}$: 2.BIP
- 0.1629: 3.MD
- 0.0470: 4.ASD
- 0.1590: 5.ADH
- 0.3724: 6.TS
- 0.3189: 7.ANO
- 0.1137: 8.OCD

FE summary

PM-Plot
rs4391122 (Meta $P = 9.6 \times 10^{-11}$)

**Gene:** ZSWIM6

**GWAS P-value**
- $8.28 \times 10^{-3}$
- 0.0084
- 0.7234
- 0.0309
- 0.9055
- 0.4379
- 0.9264
- 0.9096

**PM–Plot**

Log odds ratio

GWAS P–value

FE summary

m–value

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs4481150 (Meta $P = 4.79 \times 10^{-17}$)

Gene: ITIH3, ITIH4

GWAS P-value

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.12 x 10^{-10}</th>
<th>1.17 x 10^{-8}</th>
<th>0.0139</th>
<th>0.0001</th>
<th>0.8474</th>
<th>0.0514</th>
<th>0.1570</th>
<th>0.0508</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>1.SCZ</td>
<td>2.BIP</td>
<td>3.MD</td>
<td>4.ASD</td>
<td>5.ASD</td>
<td>6.TS</td>
<td>7.ANO</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs4495234 (Meta $P = 3.74 \times 10^{-8}$)

Gene: PPP2R2B

GWAS $P$–value

- $8.77 \times 10^{-6}$, SCZ
- $9.39 \times 10^{-5}$, BIP
- 0.4893, MD
- 0.0432, ASD
- 0.2198, ADHD
- 0.0142, TS
- 0.3499, ANO
- 0.0291, OCD

Log odds ratio

PM–Plot
rs4526442 (Meta $P = 4.1 \times 10^{-8}$)

Gene: ZCCHC7

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4531</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0006</td>
<td>2.BIP</td>
</tr>
<tr>
<td>7.03 x 10^{-8}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.1350</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3091</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1914</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.8222</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.6938</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

- log10(p)

CC-BY-NC-ND 4.0 International license

It is made available under a

The copyright holder for this preprint.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs4619651 (Meta $P = 1.47 \times 10^{-9}$)

Gene: $LMAN2L$, $CNNM4$

GWAS P-value

1.50 $\times$ $10^{-6}$  1.SCZ
5.21 $\times$ $10^{-9}$  2.BIP
0.2044  3.MD
0.0751  4.ASD
0.3631  5.AHD
0.6916  6.TS
0.5237  7.ANO
0.9802  8.OCD

FE summary

Log odds ratio

PM-Plot

m-value

-log$_{10}(p)$
rs4647903 (Meta $P = 1.69 \times 10^{-9}$)

Gene: $FGFR1$, $LETM2$

GWAS P-value
- $1.85 \times 10^{-6}$ • 1.SCZ
- $5.15 \times 10^{-6}$ • 2.BIP
- 0.0039 • 3.MD
- 0.0059 • 4.ASD
- 0.0220 • 5.AHD
- 0.0485 • 6.TS
- 0.2984 • 7.ANO
- 0.0855 • 8.OCD

Log odds ratio

FE summary

PM-Plot

GWAS P-value
- $1.85 \times 10^{-6}$
- $5.15 \times 10^{-6}$
- 0.0039
- 0.0059
- 0.0220
- 0.0485
- 0.2984
- 0.0855

$\log_{10}(p)$
rs4682973 (Meta $P = 4.06 \times 10^{-8}$)

**Gene**: TCAIM, TOPAZ1

**GWAS P-value**
- 0.0037 - SCZ
- 0.5946 - BIP
- $6.97 \times 10^{-8}$ - MD
- 0.4668 - ASD
- 0.1017 - ADHD
- 0.4495 - TS
- 0.8147 - ANO
- 0.0814 - OCD

**FE summary**

**PM-Plot**

---

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs4730387 (Meta $P = 2.73 \times 10^{-8}$)

Gene: (>200kb)

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0096</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.9174</td>
<td>2.BIP</td>
</tr>
<tr>
<td>1.01 x $10^{-8}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.6273</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.9825</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.8843</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.2449</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4233</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

-log10(p)
rs4766428 (Meta $P = 4.55 \times 10^{-8}$)

**Gene:** ATP2A2, IFT81

**GWAS P-value**
- $5.79 \times 10^{-10}$ 1.SCZ
- 0.3879 2.BIP
- 0.0135 3.MD
- 0.8574 4.ASD
- 0.2003 5.ASHD
- 0.1598 6.TS
- 0.5929 7.ANO
- 0.6180 8.OCD

**FE summary**

**PM-Plot**

---

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117

---

CC-BY-NC-ND 4.0 International license
It is made available under a
rs4906364 (Meta $P = 2.7e \times 10^{-12}$)

Gene: **PPP1R13B, ZFYVE21**

GWAS P-value

- $1.88 \times 10^{-12}$ (SCZ)
- $1.06 \times 10^{-5}$ (BIP)
- 0.1525 (MD)
- 0.0688 (ASD)
- 0.8483 (ADHD)
- 0.3123 (TS)
- 0.3724 (ANO)
- 0.3567 (OCD)

FE summary

Log odds ratio

PM–Plot

- $-\log_{10}(p)$
- m–value
rs4916723 (Meta $P = 1.82 \times 10^{-9}$)

**Gene:** (>200kb)

**GWAS P-value**
- 0.5189, 1.SCZ
- 0.5712, 2.BIP
- 0.0551, 3.MD
- 1.81 x $10^{-6}$, 4.ASD
- 1.72 x $10^{-8}$, 5.ASD
- 0.0299, 6.TS
- 0.6183, 7.ANO
- 0.4349, 8.OCD

**FE summary**

**PM-Plot**
rs5757717 (Meta $P = 9.07 \times 10^{-11}$)

**Gene**: RPS19BP1, ATF4

**GWAS P-value**
- $4.15 \times 10^{-10}$
- 0.0267
- 0.9203
- 0.3036
- 0.9265
- 0.2524
- 0.8046
- $2.83 \times 10^{-5}$

**PM-Plot**

**Log odds ratio**

**m-value**
Gene: \textit{L3MBTL2, CHADL}

GWAS P-value

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.08 \times 10^{-9}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.1263</td>
<td>2.BIP</td>
</tr>
<tr>
<td>9.38 \times 10^{-9}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.1200</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.8850</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0024</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.2123</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.0945</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

PM-Plot

\(- \text{log}_{10}(p)\) vs. m-value
rs6047287 (Meta $P = 2.72 \times 10^{-10}$)

Gene: KIZ

GWAS P-value

- 0.0001, red: 1.SCZ
- 0.5957, blue: 2.BIP
- 0.5504, blue: 3.MD
- 7.86 $\times 10^{-8}$, red: 4.ASD
- 1.97 $\times 10^{-5}$, red: 5.ASDH
- 0.7143, green: 6.TS
- 0.6429, green: 7.ANO
- 0.0431, green: 8.OCD

FE summary

Log odds ratio

GWAS P-value summary:

- SCZ: 0.0001
- BIP: 0.5957
- MD: 0.5504
- ASD: 7.86 $\times 10^{-8}$
- ADHD: 1.97 $\times 10^{-5}$
- TS: 0.7143
- ANO: 0.6429
- OCD: 0.0431
rs6125656 (Meta $P = 2.81 \times 10^{-9}$)

**Gene:** KCNB1, PTGIS

**GWAS P-value**
- $5.73 \times 10^{-6}$ (1.SCZ)
- $7.16 \times 10^{-5}$ (2.BIP)
- $5.91 \times 10^{-5}$ (3.MD)
- $0.0009$ (4.ASD)
- $0.6943$ (5.ASD)
- $0.7689$ (6.TS)
- $0.1187$ (7.ANO)
- $0.6954$ (8.OCD)

**FE summary**

**PM-Plot**
rs6471814 (Meta $P = 1.77 \times 10^{-8}$)

Gene: (>200kb)

GWAS P-value

- 2.25 x $10^{-8}$: Red circle (1.SCZ)
- 0.0693: Green circle (2.BIP)
- 0.0107: Blue circle (3.MD)
- 0.7389: Blue circle (4.ASD)
- 0.2374: Blue circle (5.ADHD)
- 0.2374: Blue circle (6.TS)
- 0.0128: Green circle (7.ANO)
- 0.0195: Green circle (8.OCD)

FE summary

Log odds ratio

GWAS P-value

- 2.25 x $10^{-8}$: Red circle (1.SCZ)
- 0.0693: Green circle (2.BIP)
- 0.0107: Blue circle (3.MD)
- 0.7389: Blue circle (4.ASD)
- 0.2374: Blue circle (5.ADHD)
- 0.2374: Blue circle (6.TS)
- 0.0128: Green circle (7.ANO)
- 0.0195: Green circle (8.OCD)

PM-Plot

-m-value vs -log10(p)

CC-BY-NC-ND 4.0 International license. It is made available under a which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. http://dx.doi.org/10.1101/528117doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs6694545 (Meta $P = 4.19 \times 10^{-9}$)

**Gene:** (>200kb)

<table>
<thead>
<tr>
<th>GWAS $P$-value</th>
<th>1. SCZ</th>
<th>2. BIP</th>
<th>3. MD</th>
<th>4. ASD</th>
<th>5. ADHD</th>
<th>6. TS</th>
<th>7. ANO</th>
<th>8. OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.39 $\times 10^{-9}$</td>
<td><img src="1" alt="Red" /></td>
<td><img src="1" alt="Red" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.0002</td>
<td><img src="1" alt="Red" /></td>
<td><img src="1" alt="Red" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.6175</td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.9448</td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Black" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.3769</td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.1217</td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.1220</td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
<tr>
<td>0.9557</td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
<td><img src="1" alt="Green" /></td>
</tr>
</tbody>
</table>

**Log odds ratio**

-0.10  -0.05  0.00  0.05  0.10

**PM-Plot**

- $\log_{10}(p)$
- $m$-value

0  5  10  15  20

0  0.2  0.4  0.6  0.8  1.0

---

CC-BY-NC-ND 4.0 International license
It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. [http://dx.doi.org/10.1101/528117](http://dx.doi.org/10.1101/528117)
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs6969410 (Meta $P = 4.65 \times 10^{-9}$)

**Gene**: (>200kb)

- **GWAS P-value**
  - $2.32 \times 10^{-6}$
  - 2. SCZ
  - 0.0625
  - 2. BIP
  - $1.29 \times 10^{-5}$
  - 3. MD
  - 0.0013
  - 4. ASD
  - 0.2185
  - 5. ADHD
  - 0.7461
  - 6. TS
  - 0.5971
  - 7. ANO
  - 0.0458
  - 8. OCD

**FE summary**

- **Log odds ratio**
- **m-value**

---

This content is made available under a CC-BY-NC-ND 4.0 International license. The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This preprint was not peer-reviewed. doi: bioRxiv preprint first posted online Jan. 26, 2019.
rs7071123 (Meta \( P = 9.78 \times 10^{-11} \))

**Gene:** CACNB2

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10 \times 10^{-10}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0001</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.2756</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0233</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3193</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0440</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4227</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7289</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10 \times 10^{-10}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0001</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.2756</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0233</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3193</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0440</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4227</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7289</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10 \times 10^{-10}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0001</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.2756</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0233</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3193</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0440</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4227</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7289</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio
rs7085104 (Meta $P = 3.35 \times 10^{-16}$)

Gene: AS3MT, C10orf32

GWAS P-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.03 \times 10^{-17}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>$1.45 \times 10^{-5}$</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0007</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.6490</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.2656</td>
<td>5.ADS</td>
</tr>
<tr>
<td>0.9602</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.9072</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.1988</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot
rs7193263 (Meta $P = 5.59 \times 10^{-11}$)

**Gene:** RBFOX1

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0899</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0003</td>
<td>2.BIP</td>
</tr>
<tr>
<td>9.73 x 10^{-9}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0053</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0065</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0851</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.9343</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.1886</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**Log odds ratio**

<table>
<thead>
<tr>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>-0.15</td>
</tr>
<tr>
<td>-0.10</td>
</tr>
<tr>
<td>-0.05</td>
</tr>
<tr>
<td>0.00</td>
</tr>
<tr>
<td>0.05</td>
</tr>
</tbody>
</table>

**PM-Plot**

- $\log_{10}(p)$

- m-value

---

License: CC-BY-NC-ND 4.0 International license. It is made available under a license to display the preprint in perpetuity.
rs7200826 (Meta $P = 1.35 \times 10^{-8}$)

Gene: **SHISA9**

**GWAS P-value**
- 0.2691, 1.SCZ
- 0.0011, 2.BIP
- $2.37 \times 10^{-8}$, 3.MD
- 0.8604, 4.ASD
- 0.1923, 5.ASD
- 0.8050, 6.TS
- 0.0986, 7.ANO
- 0.5679, 8.OCD

**FE summary**

**PM-Plot**
rs7405404 (Meta $P = 1.29 \times 10^{-12}$)

**Gene : (>200kb)**

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1. SCZ</th>
<th>2. BIP</th>
<th>3. MD</th>
<th>4. ASD</th>
<th>5. ADHD</th>
<th>6. TS</th>
<th>7. ANO</th>
<th>8. OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.40 x 10^{-9}</td>
<td>✓</td>
<td>0.0266</td>
<td>✓</td>
<td>1.51 x 10^{-7}</td>
<td>✓</td>
<td>0.3262</td>
<td>✓</td>
<td>0.4503</td>
</tr>
<tr>
<td>0.0005</td>
<td>✓</td>
<td>0.0005</td>
<td>✓</td>
<td>0.3262</td>
<td>✓</td>
<td>0.6465</td>
<td>✓</td>
<td>0.9736</td>
</tr>
</tbody>
</table>

**FE summary**

**PM–Plot**

- Log odds ratio
- m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs7521492 (Meta \( P = 1.23 \times 10^{-9} \))

**Gene:** (>200kb)

GWAS \( P \)-value

<table>
<thead>
<tr>
<th>( P )-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.96 ( \times 10^{-7} )</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0002</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0084</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0018</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.5969</td>
<td>5.ADHD</td>
</tr>
<tr>
<td>0.0179</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.0334</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.2464</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

\(-\log_{10}(p)\) vs \(m\)-value
rs7531118 (Meta $P = 1.02 \times 10^{-15}$)

**Gene: NEGR1**

### GWAS P-value

- 0.0116 1.SCZ
- 0.2404 2.BIP
- $1.03 \times 10^{-14}$ 3.MD
- 0.0192 4.ASD
- 0.6974 5.AHD
- 0.0905 6.TS
- 0.0142 7.ANO
- 0.3483 8.OCD

### FE summary

Log odds ratio

PM-Plot

- $-\log_{10}(p)$
- m-value

---

rs7618871 (Meta $P = 1.48 \times 10^{-8}$)

**Gene:** $STAG1$

**GWAS P-value**
- $1.46 \times 10^{-10}$ 1.SCZ
- 0.9233 2.BIP
- 0.3175 3.MD
- 0.2245 4.ASD
- 0.6537 5.ASD
- 0.5373 6.TS
- 0.2977 7.ANO
- 0.7433 8.OCD

**FE summary**

**PM–Plot**
rs7785663 (Meta $P = 2.7 \times 10^{-8}$)

Gene: $DGKI, PTN$

GWAS $P$-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.85 \times 10^{-8}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0002</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.4589</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0386</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.1817</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.7940</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.3709</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.1790</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot
rs7968921 (Meta $P = 4.67 \times 10^{-8}$)

Gene: SOX5

GWAS $P$-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0010</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.9881</td>
<td>2.BIP</td>
</tr>
<tr>
<td>$7.17 \times 10^{-8}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.5951</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3424</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.9559</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.4265</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.9575</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

$-0.08 \rightarrow -0.04 \rightarrow 0.00 \rightarrow 0.02 \rightarrow 0.04 \rightarrow 0.06$

PM-Plot

$-\log_{10}(p)$

$0 \rightarrow 5 \rightarrow 10 \rightarrow 15 \rightarrow 20$

$m$-value

$0.0 \rightarrow 0.2 \rightarrow 0.4 \rightarrow 0.6 \rightarrow 0.8 \rightarrow 1.0$
rs8054556 (Meta $P = 3.75 \times 10^{-11}$)

Gene: **TMEM219, KCTD13**

GWAS P-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>1. SCZ</th>
<th>2. BIP</th>
<th>3. MD</th>
<th>4. ASD</th>
<th>5. ADHD</th>
<th>6. TS</th>
<th>7. ANO</th>
<th>8. OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.67 \times 10^{-10}$</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.0002</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.0637</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.0179</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.2509</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.5807</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.6785</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
<tr>
<td>0.0022</td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
<td><img src="https://via.placeholder.com/15" alt="●" /></td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

m-value
rs8066384 (Meta $P = 3.22 \times 10^{-8}$)

**Gene:** RPTOR

**GWAS P-value**

- $1.97 \times 10^{-6}$ for 1.SCZ
- $4.04 \times 10^{-5}$ for 2.BIP
- 0.0636 for 3.MD
- 0.1969 for 4.ASD
- 0.2100 for 5.ASHD
- 0.4720 for 6.TS
- 0.0419 for 7.ANO
- 0.0337 for 8.OCD

**PM-Plot**

- Log odds ratio vs. $-\log_{10}(p)$
- m-value vs. log odds ratio

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs8084351 (Meta $P = 4.26 \times 10^{-12}$)

**Gene:** DCC

**GWAS P-value**
- $3.80 \times 10^{-5}$, 1.SCZ
- 0.0365, 2.BIP
- $4.26 \times 10^{-8}$, 3.MD
- 0.0292, 4.ASD
- 0.0004, 5.ASD
- 0.0017, 6.TS
- 0.3089, 7.ANO
- 0.0406, 8.OCD

**FE summary**

**PM-Plot**
**rs9360557 (Meta \( P = 3.04 \times 10^{-9} \))**

**Gene:** RIMS1

**GWAS P-value**
- 6.60 x 10^{-8}  (1.SCZ)
- 0.0053       (2.BIP)
- 4.97 x 10^{-5}  (3.MD)
- 0.0128       (4.ASD)
- 0.0454       (5.ASD)
- 0.3447       (6.TS)
- 0.0434       (7.ANO)
- 0.2894       (8.OCD)

**FE summary**

**PM-Plot**
rs9636107 (Meta $P = 3.03 \times 10^{-10}$)

Gene: **TCF4**

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.70 \times 10^{-13}$</td>
<td>SCZ</td>
</tr>
<tr>
<td>0.1960</td>
<td>BIP</td>
</tr>
<tr>
<td>0.0020</td>
<td>MD</td>
</tr>
<tr>
<td>0.1739</td>
<td>ASD</td>
</tr>
<tr>
<td>0.9055</td>
<td>ADHD</td>
</tr>
<tr>
<td>0.4039</td>
<td>TS</td>
</tr>
<tr>
<td>0.2016</td>
<td>ANO</td>
</tr>
<tr>
<td>0.7071</td>
<td>OCD</td>
</tr>
</tbody>
</table>

FE summary

- Log odds ratio

PM-Plot

- $m$-value

---

It is made available under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license. The copyright holder for this preprint. http://dx.doi.org/10.1101/528117 doi: bioRxiv preprint first posted online Jan. 26, 2019;
Gene: **SPAG16, VWC2L**

GWAS P-value

- 0.5524 1.SCZ
- 0.1810 2.BIP
- 0.0345 3.MD
- 0.1150 4.ASD
- 9.90 x 10^{-8} 5.ADH
- 0.0097 6.TS
- 0.7504 7.ANO
- 0.0013 8.OCD

FE summary

PM-Plot

GWAS P-value

- 0.5524 1.SCZ
- 0.1810 2.BIP
- 0.0345 3.MD
- 0.1150 4.ASD
- 9.90 x 10^{-8} 5.ADH
- 0.0097 6.TS
- 0.7504 7.ANO
- 0.0013 8.OCD

FE summary
rs9787523 (Meta $P = 3.57 \times 10^{-10}$)

**Gene:** SORCS3

### GWAS P-value

- **GWAS P-value**
  - 0.0001 (1) SCZ
  - 0.2015 (2) BIP
  - 1.94 x $10^{-7}$ (3) MD
  - 0.0160 (4) ASD
  - 0.0006 (5) ADHD
  - 0.0108 (6) TS
  - 0.5407 (7) ANO
  - 0.6047 (8) OCD

### FE summary

- **Log odds ratio**
  - -0.05 to 0.10

- **GWAS P-value**
  - 0.0001
  - 0.2015
  - 1.94 x $10^{-7}$
  - 0.0160
  - 0.0006
  - 0.0108
  - 0.5407
  - 0.6047

### PM-Plot

- **m-value**
  - 0.0 to 1.0
  - **-log10(p)**
    - 0 to 20

---

CC-BY-NC-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs9834970 (Meta $P = 1.83 \times 10^{-17}$)

Gene: TRANK1, DCLK3

GWAS P-value
- $5.53 \times 10^{-10}$
- $4.78 \times 10^{-4}$
- $0.2076$
- $0.3574$
- $0.0990$
- $0.1644$
- $0.8789$
- $0.0060$

FE summary

Log odds ratio

GWAS P-value
- $5.53 \times 10^{-10}$
- $4.78 \times 10^{-4}$
- $0.2076$
- $0.3574$
- $0.0990$
- $0.1644$
- $0.8789$
- $0.0060$

PM-Plot

- $-\log_{10}(p)$
- m-value

Gene: TRANK1, DCLK3
Gene: GRIN2A

GWAS P-value

- 1. SCZ: 6.77 x 10^{-9}
- 2. BIP: 1.28 x 10^{-6}
- 3. MD: 0.2735
- 4. ASD: 0.0844
- 5. ADHD: 0.1867
- 6. TS: 0.8658
- 7. ANO: 0.1287
- 8. OCD: 0.2626

FE summary

Log odds ratio

GWAS P-value

- 1. SCZ: 6.77 x 10^{-9}
- 2. BIP: 1.28 x 10^{-6}
- 3. MD: 0.2735
- 4. ASD: 0.0844
- 5. ADHD: 0.1867
- 6. TS: 0.8658
- 7. ANO: 0.1287
- 8. OCD: 0.2626

PM-Plot

m-value

GWAS P-value

- 1. SCZ: 6.77 x 10^{-9}
- 2. BIP: 1.28 x 10^{-6}
- 3. MD: 0.2735
- 4. ASD: 0.0844
- 5. ADHD: 0.1867
- 6. TS: 0.8658
- 7. ANO: 0.1287
- 8. OCD: 0.2626

FE summary

Log odds ratio
rs10043984 (Meta \( P = 1.9 \times 10^{-9} \))

Gene: \textit{KDM3B}, \textit{FAM53C}

GWAS P-value

- \(1.30 \times 10^{-7}\) 1.SCZ
- \(3.33 \times 10^{-6}\) 2.BIP
- 0.0810 3.MD
- 0.0415 4.ASD
- 0.1649 5.ASD
- 0.0686 6.TS
- 0.3263 7.ANO
- 0.0160 8.OCD

FE summary

Log odds ratio

PM-Plot

- \(-\log_{10}(p)\)

- m-value
rs10108980 (Meta $P = 4.15 \times 10^{-10}$)

Gene: **CSMD1**

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.56 \times 10^{-8}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.8808</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.4735</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.8105</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.7088</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0003</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.0009</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3406</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

PM–Plot

Log odds ratio

-0.05  0.00  0.05  0.10  0.15  0.20

Log10(P)

0  5  10  15  20

m–value

0.0  0.2  0.4  0.6  0.8  1.0
**rs10149470** (Meta $P = 4.8 \times 10^{-13}$)

**Gene:** *BAG5, APOPT1*

**GWAS P-value**

<table>
<thead>
<tr>
<th>P-value</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0008</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0105</td>
<td>2.BIP</td>
</tr>
<tr>
<td>$3.26 \times 10^{-9}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>$8.75 \times 10^{-5}$</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.2713</td>
<td>5.ASHD</td>
</tr>
<tr>
<td>0.0083</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6941</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4682</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**Log odds ratio**

**PM-Plot**

---

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
Gene: HSPE1–MOB4, MOB4

GWAS P-value

- \(4.84 \times 10^{-9}\)
- 0.3238
- 0.0030
- 0.5974
- 0.1531
- 0.0624
- 0.0152
- 0.0719

Log odds ratio

PM-Plot

GWAS P-value

- \(4.84 \times 10^{-9}\)
- 0.3238
- 0.0030
- 0.5974
- 0.1531
- 0.0624
- 0.0152
- 0.0719

- \(-\log_{10}(p)\)

m-value

FE summary

rs10211550 (Meta \( P = 1.37 \times 10^{-8} \))

GWAS P-value

- \(4.84 \times 10^{-9}\)
- 0.3238
- 0.0030
- 0.5974
- 0.1531
- 0.0624
- 0.0152
- 0.0719

- \(-\log_{10}(p)\)

m-value

FE summary

rs10211550 (Meta \( P = 1.37 \times 10^{-8} \))
rs10265001 (Meta $P = 4.93 \times 10^{-9}$)

**Gene:** MRPS33, BRAF

GWAS P-value

- 0.0011 • 1.SCZ
- 1.31 x $10^{-7}$ • 2.BIP
- 0.0008 • 3.MD
- 0.0008 • 4.ASD
- 0.5910 • 5.ASD
- 0.9701 • 6.TS
- 0.6232 • 7.ANO
- 0.0198 • 8.OCD

FE summary

Log odds ratio

GWAS P-value

- 0.0011 • 1.SCZ
- 1.31 x $10^{-7}$ • 2.BIP
- 0.0008 • 3.MD
- 0.0008 • 4.ASD
- 0.5910 • 5.ASD
- 0.9701 • 6.TS
- 0.6232 • 7.ANO
- 0.0198 • 8.OCD

PM–Plot

- m-value
- $-\log_{10}(p)$
rs10491964 (Meta $P = 2.4 \times 10^{-8}$)

**Gene**: CACNA1C

**GWAS P-value**

- 6.58 x $10^{-8}$  → 1.SCZ
- 0.0010  → 2.BIP
- 3.08 x $10^{-5}$  → 3.MD
- 0.8527  → 4.ASD
- 0.0789  → 5.ASD
- 0.7110  → 6.TS
- 0.8903  → 7.ANO
- 0.9769  → 8.OCD

**FE summary**

- Log odds ratio
  - -0.10
  - -0.06
  - -0.02
  - 0.02
  - 0.06

**PM-Plot**

- $-\log_{10}(p)$
  - 0
  - 5
  - 10
  - 15
  - 20

- m-value
  - 0.0
  - 0.2
  - 0.4
  - 0.6
  - 0.8
  - 1.0
rs10514301 (Meta $P = 1.87 \times 10^{-9}$)

Gene: MEF2C

GWAS P–value

<table>
<thead>
<tr>
<th>P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.ASD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5840</td>
<td>green</td>
<td>green</td>
<td>red</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.0229</td>
<td>green</td>
<td>green</td>
<td>red</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>3.22 x $10^{-10}$</td>
<td>red</td>
<td>red</td>
<td>red</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.1062</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.6830</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.0239</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.0188</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
<tr>
<td>0.8244</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
<td>green</td>
</tr>
</tbody>
</table>

FE summary
rs10745841 (Meta $P = 1.05 \times 10^{-8}$)

Gene: ANKS1B

**GWAS P-value**
- $6.00 \times 10^{-7}$
- $4.57 \times 10^{-7}$
- 1. SCZ
- 2. BIP
- 3. MD
- 4. ASD
- 5. ADHD
- 6. TS
- 7. ANO
- 8. OCD

**Log odds ratio**
- $-0.08$
- $-0.04$
- 0.00
- 0.04
- 0.08

**PM-Plot**

---

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs10791097 (Meta $P = 2.38 \times 10^{-10}$)

Gene: SNX19

GWAS P-value

- $2.10 \times 10^{-12}$
- 0.0305
- 0.0286
- 0.9772
- 0.1546
- 0.2140
- 0.4574
- 0.9952

FE summary

Log odds ratio

PM-Plot

GWAS P-value

- $2.10 \times 10^{-12}$
- 0.0305
- 0.0286
- 0.9772
- 0.1546
- 0.2140
- 0.4574
- 0.9952

FE summary

Log odds ratio

PM-Plot
rs10883832 (Meta \( P = 2.54 \times 10^{-14} \))

Gene: *NT5C2, CNNM2*

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.85 ( \times ) 10^{-16}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0006</td>
<td>2.BIP</td>
</tr>
<tr>
<td>3.65 ( \times ) 10^{-5}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.9736</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0446</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1113</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6019</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3036</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

PM-Plot

FE summary

Log odds ratio vs m-value
rs11231640 (Meta $P = 8.32 \times 10^{-9}$)

**Gene:** *RCOR2, MARK2*

**GWAS P-value**
- $2.63 \times 10^{-6}$ for SCZ
- $2.14 \times 10^{-6}$ for BIP
- $4.43 \times 10^{-5}$ for MD
- 0.6118 for ASD
- 0.1051 for ADHD
- 0.0676 for TS
- 0.0372 for ANO
- 0.5800 for OCD

**PM-Plot**

---

(Preprint) CC-BY-NC-ND 4.0 International license

(Preprint) doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs11570190 (Meta $P = 1.23 \times 10^{-10}$)

Gene: **CTNND1, BTBD18**

GWAS P-value

- $9.39 \times 10^{-7}$, red circle, 1.SCZ
- 0.8545, green square, 2.BIP
- $8.56 \times 10^{-7}$, red circle, 3.MD
- 0.0087, red circle, 4.ASD
- 0.0005, red circle, 5.ADHD
- 0.4116, green square, 6.TS
- 0.7037, green square, 7.ANO
- 0.0319, red circle, 8.OCD

FE summary

Log odds ratio

PM-Plot

$-\log_{10}(p)$, m-value

CC-BY-NC-ND 4.0 International license

The copyright holder for this preprint.
rs11658257 (Meta \( P = 1.81 \times 10^{-8} \))

**Gene:** GID4, ATPAF2

**GWAS P-value**
- 8.56 x 10^{-9} for 1.SCZ
- 0.6831 for 2.BIP
- 0.1951 for 3.MD
- 0.0118 for 4.ASD
- 0.1583 for 5.AHD
- 0.9206 for 6.TS
- 0.6521 for 7.ANO
- 0.0020 for 8.OCD

**FE summary**

**PM-Plot**

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
rs11688767 (Meta P = 2.34 x 10^{-14})

Gene: (>200kb)

GWAS P-value

- 5.06 x 10^{-11} 1.SCZ
- 0.0048 2.BIP
- 6.18 x 10^{-9} 3.MD
- 0.0556 4.ASD
- 0.1139 5.ASHD
- 0.8568 6.TS
- 0.1295 7.ANO
- 0.4148 8.OCD

FE summary

Log odds ratio

PM-Plot

\(-\log_{10}(p)\)

m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs11693528 (Meta $P = 9.77 \times 10^{-13}$)

**Gene:** C2orf69, TYW5

**GWAS P-value**
- $4.07 \times 10^{-14}$
- $8.12 \times 10^{-5}$
- 1. SCZ
- 2. BIP
- 3. MD
- 4. ASD
- 5. ADHD
- 6. TS
- 7. ANO
- 8. OCD

**FE summary**

**PM–Plot**
rs11866581 (Meta $P = 2.21 \times 10^{-8}$)

Gene: (>200kb)

GWAS P-value

- 3.77 x 10^{-5} – 1.SCZ
- 0.9525 – 2.BIP
- 1.10 x 10^{NA} – 3.MD
- 0.1034 – 4.ASD
- 0.0372 – 5.ASD
- 0.9152
- 0.1232
- 0.4343

$\log_{10}(p)$
rs11874716 (Meta $P = 8.26 \times 10^{-9}$)

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.00 \times 10^{-9}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.1172</td>
<td>2.BIP</td>
</tr>
<tr>
<td>$7.15 \times 10^{-6}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.7138</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3393</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.2812</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6339</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.9906</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

$-\log_{10}(p)$
rs11887562 (Meta $P = 2.79 \times 10^{-8}$)

Gene: (>200kb)

GWAS P-value
- $9.97 \times 10^{-8}$ 1.SCZ
- $6.95 \times 10^{-5}$ 2.BIP
- 0.0007 3.MD
- 0.8789 4.ASD
- 0.9013 5.AHD
- 0.8583 6.TS
- 0.4416 7.ANO
- 0.1034 8.OCD

FE summary

Log odds ratio

PM-Plot
rs12129573 (Meta \( P = 5.2 \times 10^{-17} \))

Gene: (>200kb)

**GWAS P-value**

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.05 \times 10^{-10}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0233</td>
<td>2.BIP</td>
</tr>
<tr>
<td>5.21 \times 10^{-12}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0723</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0010</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.4873</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.3424</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3022</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**FE summary**

**PM-Plot**

- log10(p) vs m-value
rs12474906 (Meta $P = 8.05 \times 10^{-9}$)

Gene: RBKS, MRPL33

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.60 x $10^{-8}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>9.85 x $10^{-5}$</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0036</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.7347</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.6315</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.7065</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.8131</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.0202</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

-log_{10}(p)
rs12658451 (Meta $P = 1.55 \times 10^{-16}$)

Gene: (>200kb)

GWAS P-value

<table>
<thead>
<tr>
<th>Gene</th>
<th>GWAS P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.SCZ</td>
<td>$2.56 \times 10^{-5}$</td>
</tr>
<tr>
<td>2.BIP</td>
<td>0.0069</td>
</tr>
<tr>
<td>3.MD</td>
<td>$1.69 \times 10^0$</td>
</tr>
<tr>
<td>4.ASD</td>
<td>$1.30 \times 10^{-5}$</td>
</tr>
<tr>
<td>5.ASD</td>
<td>$7.16 \times 10^{-6}$</td>
</tr>
<tr>
<td>6.TS</td>
<td>0.0055</td>
</tr>
<tr>
<td>7.ANO</td>
<td>0.0011</td>
</tr>
<tr>
<td>8.OCD</td>
<td>0.5018</td>
</tr>
</tbody>
</table>

FE summary

PM-Plot

- log$_{10}$(p) vs m-value
rs12668848 (Meta $P = 1.15 \times 10^{-13}$)

**Gene:** MAD1L1

GWAS P-value

- $1.39 \times 10^{-13}$ for SCZ
- $3.13 \times 10^{-6}$ for BIP
- $0.0107$ for MD
- $0.8637$ for ASD
- $0.9244$ for ADHD
- $0.2225$ for TS
- $0.3881$ for ANO
- $0.7120$ for OCD

FE summary

PM-Plot
rs12704290 (Meta $P = 2.83 \times 10^{-10}$)

Gene: **GRM3, KIAA1324L**

GWAS $P$-value

- 2.68 x $10^{-10}$ 1.SCZ
- 2.39 x $10^{-5}$ 2.BIP
- 0.3171 3.MD
- 0.1567 4.ASD
- 0.2381 5.ASD
- 0.9785 6.TS
- 0.7366 7.ANO
- 0.8686 8.OCD

PM-Plot

FE summary

Log odds ratio

$-0.15 \quad -0.10 \quad -0.05 \quad 0.00 \quad 0.05 \quad 0.10$

$0.0 \quad 0.2 \quad 0.4 \quad 0.6 \quad 0.8 \quad 1.0$

$0 \quad 5 \quad 10 \quad 15 \quad 20$

$-\log_{10}(p)$

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

rs12712388 (Meta $P = 1.02 \times 10^{-10}$)

Gene: (>200kb)

GWAS $P$-value
- $8.29 \times 10^{-7}$ 1.SCZ
- 0.0001 2.BIP
- $1.32 \times 10^{-6}$ 3.MD
- 0.3569 4.ASD
- 0.0038 5.AHD
- 0.9506 6.TS
- 0.7974 7.ANO
- 0.1711 8.OCD

Log odds ratio

FE summary

PM-Plot

$-\log_{10}(p)$ vs. $m$-value

CC-BY-NC-ND 4.0 International license
It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs12826178 (Meta $P = 6.01 \times 10^{-10}$)

Gene: \textit{SHMT2, NXPH4}

GWAS $P$-value

- $5.43 \times 10^{-2}$: 1.SCZ
- 0.4976: 2.BIP
- 0.2372: 3.MD
- 0.1034: 4.ASD
- 0.9421: 5.AHD
- 0.2369: 6.TS
- 0.8823: 7.ANO
- 0.6241: 8.OCD

FE summary

![Log odds ratio vs. m-value plot](image)
rs12894153 (Meta $P = 2.32 \times 10^{-8}$)

Gene: *RTN1*

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.01 x 10^{-6}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.5344</td>
<td>2.BIP</td>
</tr>
<tr>
<td>7.05 x 10^{-7}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.5838</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.6471</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.3577</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.7296</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7001</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

- Log odds ratio

PM-Plot

- $-\log_{10}(p)$

CC-BY-NC-ND 4.0 International license

It is made available under a which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs12898460 (Meta $P = 4.36 \times 10^{-8}$)

Gene: *C15orf53*

GWAS P-value

- 0.1495 1.SCZ
- $6.26 \times 10^{-8}$ 2.BIP
- 0.3659 3.MD
- 0.6099 4.ASD
- 0.0058 5.AHD
- 0.0011 6.TS
- 0.1853 7.ANO
- 0.8857 8.OCD

FE summary

Log odds ratio

PM-Plot

m-value

- $-\log_{10}(p)$

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint. http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs12958048 (Meta $P = 1.04 \times 10^{-12}$)

Gene: TCF4

GWAS P-value

- 2.60 $\times$ 10$^{-5}$, SCZ
- 0.0440, BIP
- 3.40 $\times$ 10$^{-11}$, MD
- 0.7766, ASD
- 0.3520, ADHD
- 0.6021, TS
- 0.3509, ANO
- 0.8370, OCD

Log odds ratio

-0.08 -0.04 0.00 0.04 0.08

PM-Plot
rs13217619 (Meta $P = 1.04 \times 10^{-27}$)

**Gene:** ZSCAN31, ZKSCAN3

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.91 x 10^{-29}</td>
<td>SCZ</td>
</tr>
<tr>
<td>9.76 x 10^{-5}</td>
<td>BIP</td>
</tr>
<tr>
<td>5.71 x 10^{-7}</td>
<td>MD</td>
</tr>
<tr>
<td>0.1541</td>
<td>ASD</td>
</tr>
<tr>
<td>0.2659</td>
<td>ADHD</td>
</tr>
<tr>
<td>0.6853</td>
<td>TS</td>
</tr>
<tr>
<td>0.6070</td>
<td>ANO</td>
</tr>
<tr>
<td>0.0255</td>
<td>OCD</td>
</tr>
</tbody>
</table>

**FE summary**

![Graphical representation of GWAS results with log odds ratio and m-value plots](image-url)
rs13240464 (Meta $P = 5.55 \times 10^{-11}$)

Gene: **IMMP2L**

**GWAS P-value**

- **3.47 x 10^{NA}** 1.SCZ
- **0.0782** 2.BIP
- **0.1525** 3.MD
- **0.7698** 4.ASD
- **0.1041** 5.ADHD
- **0.0265** 6.TS
- **0.1340** 7.ANO
- **0.0814** 8.OCD

**FE summary**

**PM-Plot**
rs28669119 (Meta $P = 1.64 \times 10^{-9}$)

Gene: $MEF2C$

GWAS P-value

- $1.38 \times 10^{-6}$  - 1.SCZ
- $0.1446$  - 2.BIP
- $0.0196$  - 3.MD
- $0.3963$  - 4.ASD
- $3.09 \times 10^{-6}$  - 5.ASD
- $0.3651$  - 6.TS
- $0.4284$  - 7.ANO
- $0.0513$  - 8.OCD

FE summary

Log odds ratio

GWAS P-value

- $1.38 \times 10^{-6}$
- $0.1446$
- $0.0196$
- $0.3963$
- $3.09 \times 10^{-6}$
- $0.3651$
- $0.4284$
- $0.0513$

PM-Plot

- $- \log_{10}(p)$
- m-value

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint.

http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs28681284 (Meta $P = 5.59 \times 10^{-12}$)

Gene: **CHRNA3, CHRN4**

GWAS $P$-value

- 5.77 x $10^{-13}$
- 0.0058
- 0.4706
- 0.2740
- 0.0287
- 0.0120
- 0.1801
- 0.1634

Log odds ratio vs. m-value

FE summary

GWAS P-value summary

Gene: CHRNA3, CHRN4

GWAS $P$-value

- 5.77 x $10^{-13}$
- 0.0058
- 0.4706
- 0.2740
- 0.0287
- 0.0120
- 0.1801
- 0.1634

Log odds ratio vs. m-value

FE summary

GWAS P-value summary
rs34215985 (Meta $P = 3 \times 10^{-10}$)

**Gene:** SLC30A9, DCAF4L1

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.ASD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0588</td>
<td>▢</td>
<td>⬤</td>
<td>⬤</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.2426</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.0009</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.0221</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.1441</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.0614</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
<tr>
<td>0.3126</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
<td>▢</td>
</tr>
</tbody>
</table>

**FE summary**

- log10(p)

- m-value
rs35225200 (Meta $P = 1.11 \times 10^{-10}$)

Gene: **SLC39A8**

**GWAS P-value**

- 9.83 x $10^{-3}$: SCZ
- 0.1250: BIP
- 0.2774: MD
- 0.1051: ASD
- 0.9207: ADHD
- 0.6680: TS
- 0.4772: ANO
- 0.2346: OCD

**Log odds ratio**

- $-0.20$ to $0.15$

**FE summary**

**PM–Plot**

- $-\log_{10}(p)$
- $m$-value

CC-BY-NC-ND 4.0 International license
It is made available under a
which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs35346733 (Meta $P = 7.71 \times 10^{-10}$)

**Gene:** CNTN4

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.47 \times 10^{-10}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>$9.09 \times 10^{-5}$</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.1652</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.7346</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.4814</td>
<td>5.AHD</td>
</tr>
<tr>
<td>0.6099</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6151</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.2929</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

**FE summary**

Log odds ratio

PM-Plot

m-value

-\log_{10}(p)$
rs35610290 (Meta $P = 1.54 \times 10^{-10}$)

**Gene:** (>200kb)

**GWAS P-value**
- $4.30 \times 10^{-8}$ (1.SCZ)
- $3.62 \times 10^{-7}$ (2.BIP)
- 0.2057 (3.MD)
- 0.8646 (4.ASD)
- 0.8898 (5.ASD)
- 0.7563 (6.TS)
- 0.5839 (7.ANO)
- 0.0436 (8.OCD)

**FE summary**

**PM-Plot**

Log odds ratio vs. m-value plot.
rs35774874 (Meta $P = 1.84 \times 10^{-9}$)

Gene: *SNX19*

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.31 x $10^{-9}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0001</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.2790</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.7939</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.6302</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.5328</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.0502</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.8650</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

Log odds ratio

FE summary

PM-Plot
rs36063234 (Meta $P = 5.11 \times 10^{-10}$)

Gene: NPAS3

GWAS $P$-value

<table>
<thead>
<tr>
<th>$P$-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9887</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>$1.48 \times 10^{-5}$</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0052</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0002</td>
<td>4.ASD</td>
</tr>
<tr>
<td>$3.40 \times 10^{-5}$</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.0020</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.8781</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3821</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

PM–Plot

Log odds ratio

GWAS $P$-value

-0.20 -0.15 -0.10 -0.05 0.00 0.05 0.10

$-\log_{10}(p)$

0 5 10 15 20

$m$–value

0.0 0.2 0.4 0.6 0.8 1.0

0.0 0.2 0.4 0.6 0.8 1.0
rs55648125 (Meta $P = 8.74 \times 10^{-9}$)

Gene: TFAP2B, TFAP2D

GWAS P-value

- 0.0007, 1.SCZ
- 5.14 x 10^{-8}, 2.BIP
- 0.0990, 3.MD
- 0.0019, 4.ASD
- 0.0037, 5.AHD
- 0.7638, 6.TS
- 0.1441, 7.ANO
- 0.8040, 8.OCD

Log odds ratio

FE summary

PM-Plot

GWAS P-value
rs55661361 (Meta \( P = 2.02 \times 10^{-11} \))

Gene: \( NRGN, \ VSIG2 \)

GWAS P-value

- \( 1.09 \times 10^{-11} \) for SCZ
- \( 0.1372 \) for BIP
- \( 0.2241 \) for MD
- \( 0.0011 \) for ASD
- \( 0.0551 \) for ADHD
- \( 0.7894 \) for TS
- \( 0.9711 \) for ANO
- \( 0.2651 \) for OCD

FE summary

Log odds ratio

PM–Plot

\(-\log_{10}(p)\)
rs58235352 (Meta $P = 4.71 \times 10^{-8}$)

**Gene**: ACADS, SPPL3

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0798</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0015</td>
<td>2.BIP</td>
</tr>
<tr>
<td>$1.26 \times 10^{-7}$</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.1157</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.6739</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1084</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.2321</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.8092</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

Log odds ratio: $-0.25 - 0.15 - 0.05 0.05 0.10 0.15$

FE summary

PM-Plot

- log10(p) vs m-value
rs59979824 (Meta $P = 4.46 \times 10^{-9}$)

**Gene:** (>200kb)

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1.SCZ</th>
<th>2.BIP</th>
<th>3.MD</th>
<th>4.ASD</th>
<th>5.AHD</th>
<th>6.TS</th>
<th>7.ANO</th>
<th>8.OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.42 x 10^{-9}</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.0001</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.8474</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.1483</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.6421</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.7556</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.0812</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>0.5112</td>
<td>🔴</td>
<td>🔴</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
</tbody>
</table>

FE summary

![PM-Plot](https://example.com/pm_plot.png)

Log odds ratio

m-value

CC-BY-NC-ND 4.0 International license
It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117

**doi:** bioRxiv preprint first posted online Jan. 26, 2019;
rs61867293 (Meta $P = 7.81 \times 10^{-15}$)

Gene: SORCS3

GWAS P-value
- $4.96 \times 10^{-6}$ - 1.SCZ
- 0.0073 - 2.BIP
- $8.71 \times 10^{-10}$ - 3.MD
- 0.0029 - 4.ASD
- $1.95 \times 10^{-7}$ - 5.AHD
- 0.3855 - 6.TS
- 0.0321 - 7.ANO
- 0.6997 - 8.OCD

FE summary

Log odds ratio

GWAS $P$-value
- 0.0073
- $4.96 \times 10^{-6}$
- $8.71 \times 10^{-10}$
- 0.0029
- $1.95 \times 10^{-7}$
- 0.3855
- 0.0321
- 0.6997

PM-Plot

m-value

$-\log_{10}(p)$
**rs61882743 (Meta $P = 1.15 \times 10^{-8}$)**

*Gene: AMBRA1, HARBI1*

**GWAS P-value**
- $2.71 \times 10^{-10}$
- 0.2932
- 0.0439
- 0.1328
- 0.0070
- 0.7089
- 0.1963
- 0.7055

**Log odds ratio**

- 1.0
- 0.5
- 0.0
- -0.5
- -1.0

**PM-Plot**

- PM - value
- -log10(p)
- m-value

**CC-BY-NC-ND 4.0 International license**

This preprint has not been peer-reviewed. It is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. For more information, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
rs62526783 (Meta $P = 2.34 \times 10^{-8}$)

**Gene:** (>200kb)

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>SCZ</th>
<th>BIP</th>
<th>MD</th>
<th>ASD</th>
<th>ADHD</th>
<th>TS</th>
<th>ANO</th>
<th>OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.18 x 10^{-9}</td>
<td>0.0144</td>
<td>0.3088</td>
<td>0.0132</td>
<td>0.4150</td>
<td>0.5069</td>
<td>0.8647</td>
<td>0.1750</td>
<td></td>
</tr>
</tbody>
</table>

**Log odds ratio**

FE summary

**PM-Plot**

- $\log_{10}(p)$
- $m$-value
rs71395455 (Meta $P = 5.43 \times 10^{-14}$)

Gene: **ZSCAN2, WDR73**

GWAS $P$-value

- 2.30 x $10^{-9}$ (red, circle 1: SCZ)
- 1.87 x $10^{-8}$ (red, circle 2: BIP)
- 0.0079 (blue, circle 3: MD)
- 0.0007 (red, circle 4: ASD)
- 0.4803 (blue, circle 5: ADHD)
- 0.4105 (blue, circle 6: TS)
- 0.9922 (green, circle 7: ANO)
- 0.9341 (green, circle 8: OCD)

FE summary

PM–Plot

$-\log_{10}(p)$
rs75059851 (Meta $P = 5.85 \times 10^{-10}$)

Gene: **IGSF9B**

GWAS $P$-value

- $1.90 \times 10^{-11}$ (1.SCZ)
- 0.1245 (2.BIP)
- 0.6802 (3.MD)
- 0.7897 (4.ASD)
- 0.0292 (5.ADHD)
- 0.9859 (6.TS)
- 0.0443 (7.ANO)
- 0.6261 (8.OCD)

FE summary

Log odds ratio

-0.15 -0.10 -0.05 0.00 0.05 0.10 0.15

PM-Plot

- $\log_{10}(p)$

0 5 10 15 20

0.0 0.2 0.4 0.6 0.8 1.0

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint. http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs77135925 (Meta $P = 7.73 \times 10^{-9}$)

Gene: MYO18A, CRYBA1

GWAS P-value

- 0.6369, 1.SCZ
- 0.0040, 2.BIP
- 9.92 $\times 10^{-9}$, 3.MD
- 0.4653, 4.ASD
- 0.3377, 5.AHD
- 0.7981, 6.TS
- 0.0303, 7.ANO
- 0.3456, 8.OCD

FE summary

Log odds ratio

GWAS P-value

- 0.6369, 1.SCZ
- 0.0040, 2.BIP
- 9.92 $\times 10^{-9}$, 3.MD
- 0.4653, 4.ASD
- 0.3377, 5.AHD
- 0.7981, 6.TS
- 0.0303, 7.ANO
- 0.3456, 8.OCD

PM-Plot

$-\log_{10}(p)$
rs78337797 (Meta $P = 4.98 \times 10^{-8}$)

Gene: **SOX5**

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>SCZ</th>
<th>BIP</th>
<th>MD</th>
<th>ASD</th>
<th>ADHD</th>
<th>TS</th>
<th>ANO</th>
<th>OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0281</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.68 x 10^{-6}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0096</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1656</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2353</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.9478</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.6796</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FE summary**
rs79879286 (Meta $P = 7.21 \times 10^{-11}$)

Gene: **OSBPL3, DFNA5**

GWAS P-value

- 1.96 x $10^{-5}$ (1.SCZ)
- 4.51 x $10^{-6}$ (2.BIP)
- 8.76 x $10^{-7}$ (3.MD)
- 0.0150 (4.ASD)
- 0.0705 (5.ASDH)
- 0.7519 (6.TS)
- 0.3620 (7.ANO)
- 0.5698 (8.OCD)

FE summary

Log odds ratio vs. m-value plot
rs80256351 (Meta $P = 2.56 \times 10^{-9}$)

Gene: (>200kb)

GWAS $P$-value

- $3.51 \times 10^{-7}$ 1.SCZ
- $1.15 \times 10^{-7}$ 2.BIP
- 0.0747 3.MD
- 0.5343 4.ASD
- 0.5287 5.ADH
- 0.4262 6.TS
- 0.9292 7.ANO
- 0.4587 8.OCD

FE summary

Log odds ratio

PM-Plot
rs80318442 (Meta $P = 4.03 \times 10^{-12}$)

Gene: (>200kb)

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>1. SCZ</th>
<th>2. BIP</th>
<th>3. MD</th>
<th>4. ASD</th>
<th>5. ADHD</th>
<th>6. TS</th>
<th>7. ANO</th>
<th>8. OCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.65 x $10^{-6}$</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>9.20 x $10^{-5}$</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>0.2222</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>0.2241</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>2.62 x $10^{-8}$</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>0.9884</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>0.0619</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>0.8721</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>1.00</td>
<td>0.99</td>
<td>0.99</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117

doi: bioRxiv preprint first posted online Jan. 26, 2019;
rs111294930 (Meta \( P = 2.77 \times 10^{-10} \))

Gene: (>200kb)

GWAS \( P \)-value

- 8.63 \( \times \) 10\(-10\): 1.SCZ
- 7.45 \( \times \) 10\(-6\): 2.BIP
- 0.1012: 3.MD
- 0.7809: 4.ASD
- 0.3409: 5.AHD
- 0.1137: 6.TS
- 0.9047: 7.ANO
- 0.3652: 8.OCD

FE summary

PM-Plot

\( -\log_{10}(p) \) vs \( m \)-value
rs116755193 (Meta $P = 1.04 \times 10^{-8}$)

Gene: (>200kb)

GWAS P-value

- 0.1008, 1.SCZ
- 0.0323, 2.BIP
- 5.20 x $10^{-9}$, 3.MD
- 0.5347, 4.ASD
- 0.4221, 5.ASHD
- 0.4360, 6.TS
- 0.1838, 7.ANO
- 0.0740, 8.OCD

FE summary

Log odds ratio

- GM
- PM

GWAS P-value

- 0.1008
- 0.0323
- 5.20 x $10^{-9}$
- 0.5347
- 0.4221
- 0.4360
- 0.1838
- 0.0740

m-value

- 0.0
- 0.2
- 0.4
- 0.6
- 0.8
- 1.0

- log10(p)

CC-BY-NC-ND 4.0 International license

It is made available under a license which was not peer-reviewed is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
rs117956829 (Meta $P = 1.82 \times 10^{-9}$)

Gene: **NOX4, FOLH1B**

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0002</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0794</td>
<td>2.BIP</td>
</tr>
<tr>
<td>3.27 x 10^{-7}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0068</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.9716</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.6460</td>
<td>6.TSD</td>
</tr>
<tr>
<td>0.0125</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.3330</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

m-value

$-\log_{10}(p)$
rs140505938 (Meta $P = 2.42 \times 10^{-12}$)

**Gene:** VPS45, OTUD7B

GWAS P–value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.05 x 10^-9</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>7.00 x 10^-7</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.0671</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.1240</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.4839</td>
<td>5.ASHD</td>
</tr>
<tr>
<td>0.5130</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6462</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.0053</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM–Plot

m–value

-log10(p)

GWAS P–value

1.05 x 10^-9  7.00 x 10^-7  0.0671  0.1240  0.4839  0.5130  0.6462  0.0053
rs142462188 (Meta $P = 9.68 \times 10^{-9}$)

Gene: (>200kb)

<table>
<thead>
<tr>
<th>GWAS P-value</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.57 x 10^{-5}</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.0810</td>
<td>2.BIP</td>
</tr>
<tr>
<td>1.20 x 10^{-6}</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0321</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.3491</td>
<td>5.ADHD</td>
</tr>
<tr>
<td>0.3334</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.6775</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.1257</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

GWAS P-value

GWAS P-value

PM-Plot

m-value

- log_{10}(p)
rs144158419 (Meta $P = 6.89 \times 10^{-9}$)

Gene: (>200kb)

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.15 \times 10^{-12}$</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.4760</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.1849</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.1067</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.7315</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1828</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.2911</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.7835</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

FE summary

Log odds ratio

PM-Plot

- log_{10}(p)

m-value
rs188099135 (Meta \( P = 3.05 \times 10^{-8} \))

**Gene:** \( EPHX2, CLU \)

GWAS P-value

<table>
<thead>
<tr>
<th>P-value</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.93 ( \times 10^{-8} )</td>
<td>1.SCZ</td>
</tr>
<tr>
<td>0.3781</td>
<td>2.BIP</td>
</tr>
<tr>
<td>0.6727</td>
<td>3.MD</td>
</tr>
<tr>
<td>0.0743</td>
<td>4.ASD</td>
</tr>
<tr>
<td>0.0005</td>
<td>5.ASD</td>
</tr>
<tr>
<td>0.1925</td>
<td>6.TS</td>
</tr>
<tr>
<td>0.7840</td>
<td>7.ANO</td>
</tr>
<tr>
<td>0.4992</td>
<td>8.OCD</td>
</tr>
</tbody>
</table>

- log10(p) vs m-value PM-Plot

CC-BY-NC-ND 4.0 International license

It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

http://dx.doi.org/10.1101/528117
doi: bioRxiv preprint first posted online Jan. 26, 2019;
Figure S3. Statistical power and number of cross-disorder associations (Related to Table S4). Power to detect associations across pairs of disorders was plotted with the number of cross-disorder associations identified in the current meta-analysis. For each pair of disorders, power was estimated using the number of cases and heritability for each disorder, as well as the genetic correlation between the disorders. In general, as power increased, so did the number of SNPs identified.
Statistical Power and Numbers of Cross-Disorder Associations

sqrt(N1 * h2_1 * N2 * h2_2 * rg * rg)

# of cross-disorder associations

SCZ/BIP
SCZ/MDD
SCZ/AUT
SCZ/ADD
SCZ/TS
SCZ/ANO
SCZ/OCD
BIP/MDD
BIP/AUT
BIP/ADD
BIP/TS
BIP/ANO
BIP/OCD
MDD/AUT
MDD/ADD
MDD/TS
MDD/ANO
MDD/OCD
AUT/ADD
AUT/TS
AUT/ANO
AUT/OCD
ADD/TS
ADD/ANO
ADD/OCD
TS/ANO
TS/OCD
ANO/OCD
Figure S4. Gene expression of top loci across development. (Related to Figure 3)
Gene expression trajectories from a transcriptome atlas of post-mortem brain tissue across development are plotted for four top loci, DCC, RBFOX1, NOX4 and BRAF in six different brain tissue types. AMY = amygdala; MD = mediodorsal nucleus of the thalamus; CBC = cerebellar cortex; NCX = neocortex; HIP = hippocampus; STR = striatum.
Figure S5. Gene expression in the brain for pleiotropic and non-pleiotropic loci. (Related to Figure 5) Average normalized gene expression in fetal and adult post-mortem brain tissue for pleiotropic (109) and non-pleiotropic (37) loci were plotted. Disorder-specific and pleiotropic risk loci showed a similar level of gene expression in prenatal and postnatal development after multiple testing correction (t-test $p > 0.025$).